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Abstract 
Malaria represents one of the most significant threats to global health today, with half of the 
world’s population currently at risk.  Although there exist several antimalarial drugs to treat the 
disease, many of them have been used and over-used for decades, leading to widespread 
resistance in the causative Plasmodium parasite.  As a result, new antimalarials are needed not 
only to replace the old, but also to supplement each other in novel combination therapies.  Two 
such candidates are fosmidomycin and its N-acetyl analog FR-900098, Streptomycete natural 
products first identified in the 1980s.  These compounds were later found to be potent inhibitors 
of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, a necessary enzyme in Plasmodium for 
isoprenoid biosynthesis via the non-mevalonate pathway, which does not exist in humans.  
Although FR-900098 was determined to be about twice as potent as fosmidomycin, it is 
important to note that, as a Streptomycete secondary metabolite, it is by no means optimized as a 
human antimalarial drug. 
In the work presented here, we have studied and characterized the N-acetyltransferase FrbF from 
the FR-900098 biosynthetic pathway, which was recently completely reconstituted in E. coli.  
This enzyme is responsible for transfer of the acetyl group from acetyl-CoA to the phosphonate 
substrate, representing the penultimate step in FR-900098 synthesis.  By exploiting the substrate 
specificity of FrbF, we can synthesize novel derivatives of FR-900098 with alternate N-acyl 
functionalities both in vivo and in vitro, such as the N-propionyl analog FR-900098P, which was 
found to be even more potent than its parent compound.  We have also heterologously expressed 
and characterized the target enzyme from P. falciparum, which serves as a tool to evaluate the 
effectiveness of novel antimalarial compounds.  Finally, we have developed a screening method 
for the directed evolution of FrbF to identify mutants with altered substrate specificity. 
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Chapter 1: Introduction to the antimalarial phosphonic acid FR-
900098 
 
1.1 Malaria: an ongoing global health issue 
1.1.1 The malaria threat 
With 225 million cases and 781,000 deaths estimated in 2009 alone, malaria remains one of the 
most significant threats to global health today [1].  Despite past and current control efforts, about 
half of the world’s population still remains at risk.  The disease is caused by any of four different 
species of Plasmodia – Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, and 
Plasmodium ovale – all of which are transmitted to human hosts through mosquitoes of the 
genus Anopheles.  Of these four parasite species, Plasmodium falciparum and Plasmodium vivax 
are the most common.  Common symptoms of malaria include headache, fever, chills, and 
vomiting, and can become significantly more severe without treatment, leading to anemia, 
respiratory distress, encephalopathy (cerebral malaria), and death [2].  Children under five years 
of age are particularly susceptible to the disease, accounting for 85 % of the reported deaths. 
 
1.1.2 Past eradication efforts 
Efforts to stop malaria began around the turn of the 20
th
 century, when the distribution of the 
disease included significant portions of North America, Europe, and northern Asia (Figure 1.1).  
During that time, the focus of these efforts was environmental control of the mosquito vector and 
its breeding sites [3].  The discovery of the insecticidal properties of 
dichlorodiphenyltrichloroethane (DDT) in the 1940s greatly aided this cause.  In 1955, the World 
Health Organization ambitiously launched its Global Malaria Eradication campaign, which relied 
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on a combination of widespread insecticide usage and mass drug administration.  In the 
developed world, this approach proved to be quite successful (Figure 1.1).  However, it 
eventually became evident that the goal of complete eradication was not feasible.  Notably, this 
effort ignored the majority of sub-Saharan Africa, where the infrastructure did not exist to follow 
through on the plan [4].   
 
Despite the great general effectiveness of insecticides, insecticide resistance in Anopheles 
mosquitoes was first reported in the mid-1950s [5].  Further, mass drug administration was 
carried out primarily using only one of two antimalarial compounds: chloroquine or 
pyrimethamine (Figure 1.2).  As a result, early effectiveness was hampered by the development 
of resistance as high selection pressure was applied, and reports of chloroquine-resistant and 
pyrimethamine-resistant malaria followed [6-8].  In 1969, the WHO concluded that global 
malaria eradication was no longer a feasible goal, and so financial support for the Campaign was 
rapidly reduced.  Subsequently, the malaria problem continued to grow throughout the 1970s, 
1980s, and early 1990s, up to the point where 300 – 500 million cases and 1.5 – 2.7 million 
deaths were estimated in 1994 [9]. 
 
1.1.3 Current control efforts 
The current era of malaria control began in 1993 with the WHO’s adoption of the new Global 
Malaria Control Strategy.  This plan called for more disease-focused action, advocating rational, 
locally-tailored control efforts [4].  By 1998, the Roll Back Malaria Partnership was formed and 
established clear goals for malaria control in 2010, 2015, and beyond.  These goals call for the 
parallel implementation of locally appropriate vector control methods (including insecticide-
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treated bed nets and indoor residual spraying) and effective diagnosis and treatment of infected 
individuals [10].  Chief among the malaria treatments are so-called ACTs, or artemisinin 
combination therapies. 
 
Artemisinin, a sesquiterpene lactone derived from the plant Artemisia annua (Figure 1.2), has a 
long history of human therapeutic use.  Known as qing hao in China, the plant was first 
referenced in 168 BC as a treatment for hemorrhoids, and in 340 AD was noted as a treatment 
for fever, first suggesting its antimalarial capabilities [11].  In 1972, artemisinin was first isolated 
from Artemisia annua.  Subsequent assays against Plasmodium falciparum demonstrated 
significant potency, comparable to that of chloroquine and mefloquine.  Trials in mice also 
showed good efficacy in treating P. berghei, and a 1979 human trial cured 2099 patients, 
although moderate recrudescence was observed [12]. 
 
Although the cultivated native producer continues to be the primary source of artemisinin, 
demand for the compound still exceeds the practical output of this effort [13].  To solve this 
problem, total synthesis of the compound was attempted by several research groups in the 1980s 
and 1990s.  Although multiple total syntheses were achieved, none were suitable for 
commercialization [14-17].  As vast improvements were made in recombinant DNA technology 
around the turn of the century, biosynthesis became a much more attractive alternative.  Efforts 
toward the biosynthesis of artemisinin were spearheaded by the research group of Jay Keasling.  
In 2003, they demonstrated synthesis of the artemisinin precursor amorphadiene in Escherichia 
coli via an engineered mevalonate pathway from Saccharomyces cerevisiae and a synthetic 
amorpha-4,11-diene synthase gene [18].  In 2006, artemisinic acid titers of up to 100 mg•L-1 
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were achieved in an engineered S. cerevisae, paving the way to commercially relevant 
biosynthesis [19].  By 2009, further optimization of both the heterologous mevalonate pathway 
and the overall fermentation process significantly increased amorphadiene titers in E. coli to and 
average of 27.4 g•L-1 [20]. 
 
Although artemisinin (and its derivatives, such as artesunate or artemether) remain the key 
component in the current malaria treatment campaign, they do not necessarily represent a 
complete solution to the ongoing malaria problem.  Evidence of artemisinin resistance has 
already been observed in field isolates, calling for urgent containment measures to stop its spread 
[21-23].  This underscores the need for new antimalarial drugs, not only to replace the old but to 
supplement each other in novel combination therapies as the fight against malaria continues. 
 
1.2 Phosphonic acids: new solutions from natural products 
1.2.1 Pharmaceuticals from natural products 
For centuries, mankind has turned to nature for ways to improve quality of life.  Microbial 
fermentation, for example, has been extensively utilized for the production of beer, bread, and 
wine, with the oldest known fermentations occurring at least 9000 years ago [24].  In the field of 
human health, use of natural products began in earnest in 1929 with Alexander Fleming’s 
discovery of the antibacterial penicillin [25].  In the ensuing decades, over one million natural 
products have been discovered from plants, animals, and microorganisms, of which 20 – 25 % 
exhibit biological activity [26].  At present, natural products continue to see extensive 
pharmaceutical use.  In the period from 1981 – 2006, approximately half of all small molecule 
NCEs (new chemical entities) were natural products, natural product derivatives, natural product 
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mimics, or synthetic analogues of natural product pharmacophores [27].  However, it is 
noteworthy that (i) the vast majority (>99 %) of microorganisms remain uncultivable in the 
laboratory setting [28] and (ii) of the sequenced microbial genomes, most contain several gene 
clusters for which the corresponding natural product is either unknown or undetected [29].  
Taking these two facts together, it can be concluded that there still exists a great wealth of as yet 
undiscovered natural products for the treatment of any number of human diseases. 
 
One class of natural products underexploited for use as human therapeutics is the phosphonic 
acids.  These compounds are characterized by the presence of a highly stable carbon-phosphorus 
(C-P) bond, which can withstand harsh treatment in strong acid or base.  These compounds are 
capable of mimicking phosphate esters and carboxylates, two of the most ubiquitous chemical 
moieties in all of biology.  As a result, they have the potential to serve as analogues of these 
compounds, and thus as potent inhibitors of a great number of enzymes [30]. 
 
Multiple phosphonic acid (and phosphinic acid, containing a C-P-C bond) natural products with 
interesting bioactivities have been discovered and characterized (Figure 1.3).  Bialaphos, for 
example, is an herbicide, the gene cluster of which was identified and characterized in 1986 [31].  
Fosfomycin, originally called phosphonomycin, was first identified from multiple Streptomyces 
species and later found to be produced by Pseudomonas syringae [32, 33].  Heterologous 
expression in Streptomyces lividans enabled identification of the minimal of the gene cluster 
from Streptomyces fradiae [34].  Currently, fosfomycin is a clinically-approved antibiotic for 
urinary tract infections and has also been found to be effective against resistant strains of 
Staphylococcus aureus.  Another phosphonate antibiotic is dehydrophos, first identified in 1984 
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[35].  This compound demonstrates broad-spectrum activity, and its biosynthetic cluster has been 
heterologously expressed and characterized [36].  These three examples represent only a fraction 
of the known naturally occurring small molecule phosphonates. 
 
1.2.2 Fosmidomycin and FR-900098 
1.2.2.1 Initial discovery and studies 
Two phosphonic acid compounds of particular interest in the antimalarial field are fosmidomycin 
(originally called FR-31564) and FR-900098.  These two compounds were first isolated in the 
late 1970s by the Fujisawa Pharmaceutical Co., Ltd. from Streptomyces lavendulae and S. 
rubellomurinus sp. nov., respectively [37, 38].  They were discovered in a screening program of 
soil isolates against the nocardicin C-supersensitive mutant of Pseudomonas aeruginosa NCTC 
10490, designed to identify novel inhibitors of cell wall biosynthesis.  The chemical structures of 
both compounds were solved at the time of isolation.  They were found to differ only in their N-
acyl groups, with fosmidomycin containing a formyl group and FR-900098 containing an acetyl 
moiety.  Antibiotic spectra for these compounds were determined using a variety of 
microorganisms in a serial dilution agar plate assay, and both were found to be much more 
effective against Gram-negative bacteria than Gram-positive.  FR-900098, in particular, was 
found to be most effective against Salmonella typhi O-901 and a Pseudomonas aeruginosa 
mutant (MICs of 2 and 1.6 µg/mL, respectively) while fosmidomycin was most effective against 
Sarcina lutea PCI-1001 and the same P. aeruginosa mutant (MICs of 0.1 and 0.05 µg/mL, 
respectively).  However, fosmidomycin was found to be at least as effective as FR-900098 
against all strains tested, often exhibiting a significantly lower MIC.  As a result, further 
development efforts and clinical trials proceeded with fosmidomycin in the 1980s [39-43].  It 
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was found to have good pharmacokinetic properties and was initially targeted as a treatment of 
urinary tract infections.  Though initial results showed promise, the drug was found to be poorly 
effective against recurrent infections, and so further development was halted [44]. 
 
1.2.2.2 Renewed interest and clinical trials 
Following its initial discovery, little subsequent research interest was expressed in FR-900098, as 
it was thought to be the inferior of the two compounds from an antibiotic standpoint.  However, 
interest in both compounds was rekindled in 1993 with the elucidation of the non-mevalonate 
pathway for the biosynthesis of isoprenoid precursors [45].  As isoprenoid synthesis was 
previously thought to be generated solely through the mevalonate pathway, the discovery of this 
alternate pathway shed light on novel targets for herbicides and antibiotics.  In 1989, it had 
already been demonstrated that fosmidomycin derived its antibiotic activity through inhibition of 
isoprenoid synthesis [46].  Kuzuyama and co-workers demonstrated this inhibition in vitro with 
purified deoxyxylulose-5-phosphate reductoisomerase (Dxr) from the non-mevalonate pathway 
in E. coli, observing mixed-mode inhibition with a Ki value of 38 nM for fosmidomycin [47].  
The full resurgence of fosmidomycin and FR-900098 was not underway until 1999, however, 
when the Jomaa research group first identified the two compounds as potential antimalarials 
[48].  In this study, bioinformatic analysis was employed to identify a possible Dxr enzyme in 
the recently sequenced genome of Plasmodium falciparum.  Fosmidomycin and FR-900098 were 
both assayed against three strains of P. falciparum.  While both compounds exhibited low IC50 
values (≤370 nM), FR-900098 that proved to be roughly twice as effective as fosmidomycin.  
This also proved true in in vitro inhibition assays against the purified recombinant target enzyme.  
Finally, animal studies were conducted in mice infected with P. vinckei.  Again, FR-900098 
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proved to be the most effective antimalarial drug, exhibiting <1 % parasitemia with a 2 mg/kg 
dosage. 
 
Likely owing to the difficulty in preparing large quantities of FR-900098, antimalarial clinical 
trials in humans instead proceeded with fosmidomycin.  The first of these trials were carried out 
in Gabon by Missinou and co-workers [49].   In this study, 27 adults with uncomplicated P. 
falciparum malaria were administered fosmidomycin (1.2 g every 8 h) for 3, 4, or 5 days.  In the 
4- and 5-day treatment groups, almost 90 % of patients had negative blood smears at day 14, 
indicating effective treatment of the disease.  In the 3-day group, however, the observed cure rate 
was only 60 %.  Nevertheless, a rapid parasite clearance time of 48 h was observed, indicating 
the effectiveness of this drug.  A second study carried out in both Gabon and Thailand utilized a 
7-day treatment regimen [50].  After 7 days, all 20 subjects were found to be cured of the 
disease.  Twenty-eight days after the onset of treatment, however, recrudescence was observed in 
two of nine patients in Gabon (one patient was unavailable for follow-up), and seven of nine 
patients in Thailand (one patient had developed P. vivax parasitemia).  These results suggested 
the limits of fosmidomycin monotherapy, inspiring subsequent trials to consider combination 
therapies.  Fosmidomycin-clindamycin was then evaluated in children of various age groups [51-
53].  Initial studies focused on children aged 7 – 14.  Patients were treated for either 1, 2, 3, 4, or 
5 days and re-evaluated at day 14.  In each of the multi-day treatment groups, 100 % cure rates 
were observed by day 14, while a cure rate of 50 % was observed with only 1 day of treatment.  
Comparison with 5-day regimens of either fosmidomycin alone or clindamycin alone clearly 
demonstrated the advantage of the combination therapy.  Extension of the subject age range 
showed similar cure rates in children as young as 3, but a significant decrease in children aged 1 
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– 2.  An alternate combination therapy of fosmidomycin-artesunate was also evaluated in 
children aged 6 – 15, revealing 100 % 14-day cure rates with dosing regimens of ≥2 days.  
Follow-up at 28 days revealed ≥90 % cure rates with dosing regimens of ≥3 days [54]. 
 
1.2.2.3 Heterologous expression and characterization 
With renewed interest in FR-900098 came renewed interest in its biosynthesis, first to elucidate 
the potentially unique biochemical transformations involved, and second to facilitate industrially 
relevant over-production through protein and metabolic engineering efforts.  Although few 
phosphonic acid gene clusters had previously been characterized, a common initial step in their 
biosyntheses was noted to be conversion of phosphoenolpyruvate (PEP) to phosphonopyruvate 
through the activity of a PEP mutase (PEPM) gene [55].  As a result, identification of the FR-
900098 biosynthetic cluster from the native producer S. rubellomurinus began with PCR-
amplification of the PEPM gene from a genomic DNA fosmid library using degenerate primers.  
One hit from this screening process was the fosmid 4G7, which was subsequently integrated into 
the chromosome of the heterologous host Streptomyces lividans.  Evaluation of the culture 
supernatant from this host against the purified E. coli Dxr and a phosphonate-sensitive E. coli 
strain confirmed that the cluster produced an active phosphonate Dxr inhibitor, and 
31
P-NMR 
and LC-MS analysis confirmed this compound to be FR-900098.  Sequencing and deletion 
analysis led to the identification of eight open reading frames (ORFs), designated frbA – frbH, 
which were found to be necessary for FR-900098 production; two additional ORFs, frbI and 
frbJ, immediately downstream of the minimal cluster but not necessary for FR-900098 
production; and one final ORF, dxrB, which appeared to be encode a Dxr homologue.  Of the 
eight requisite ORFs, frbD was found to encode the PEPM originally identified in the fosmid 
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library screening, and thus likely catalyzes the first step in FR-900098 biosynthesis.  However, 
no phosphonopyruvate decarboxylase gene was identified, which catalyzes the second step in 
other phosphonate biosyntheses.  Instead, it was proposed that the early steps of FR-900098 
biosynthesis parallel the TCA cycle, catalyzed by FrbA, FrbB, FrbC, and FrbE.  In vitro assays 
with purified FrbD and FrbC clearly demonstrated the formation of 2-phosphonomethylmalate, 
confirming FrbC to be phosphonomethylmalate synthase.  FrbA and either FrbB or FrbE (or 
both) were predicted to catalyze the subsequent TCA-analogous steps, yielding 2-oxo-4-
phosphonobutyrate.  To complete FR-900098 synthesis, FrbH was predicted to catalyze either 
the decarboxylation or transamination (or both) necessary to form 3-aminopropylphosphonate.  
Finally, acetylation of the amine was proposed to be catalyzed by FrbF, while hydroxylation of 
the amine was unassigned.  As N-acetyl-3-aminopropylphosphonate was detected in the 
supernatant of the heterologous producer, while N-hydroxy-3-aminopropylphosphonate was not, 
acetylation was presumed to occur first. 
 
As the final steps in FR-900098 biosynthesis were assigned purely based on in silico analysis, 
further research was necessary to confirm these predictions with in vitro and in vivo data.  To 
accomplish this goal, the entire FR-900098 pathway was transferred to a more tractable host: E. 
coli.  Additionally, this host would be more desirable for subsequent engineering and over-
production efforts.   The eight requisite ORFs and dxrB, thought to be involved in self-resistance, 
were placed on three compatible plasmids, each under the control of an IPTG-inducible T7 
promoter.  The result was a strain capable of reaching FR-900098 titers of 6.3 mg/L in shake-
flask cultures in LB media [56].  Additional strains containing only part of the downstream 
pathway were constructed for use in whole-cell feeding studies.  Curiously, when these strains 
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were fed 2-amino-4-phosphonobutyrate (2APn), the intermediates (detected by LC-MS) included 
CMP-5’-3-aminopropylphosphonate (CMP-5’-3APn), CMP-5’-N-acetyl-3-
aminopropylphosphonate (CMP-5’-Ac3APn), and CMP-5’-FR-900098, suggesting the inclusion 
of a nucleotide transferase in the pathway.  These feeding studies also suggested the necessity of 
frbG, the function of which had been unassigned after the initial heterologous expression in S. 
lividans. 
 
Further in silico analysis of FrbH revealed the presence of both a PLP-dependent 
aminotransferase/decarboxylase domain and a nucleotide transferase domain.  In vitro assays 
with the purified enzyme demonstrated the functionality of both of these domains in the 
conversion of 2APn to CMP-5’-3APn.  Subsequent in vitro assays were carried out with FrbF 
and FrbG, the flavin-dependent monooxygenase now thought to catalyze amine hydroxylation.  
Interestingly, both substrates were found to be active toward the FrbH product CMP-5’-3APn; 
FrbF, however, was also found to be active toward the hydroxylamine derivative, while FrbG 
was not active toward the N-acetyl derivative.  Thus, the path to CMP-5’-FR-900098 was 
concluded to proceed first via hydroxylation and then acetylation, with the N-acetyl derivative 
appearing as a dead-end side product (Figure 1.4).  As demonstrated in the heterologous hosts, 
formation of the final product FR-900098 could be achieved simply through a ubiquitous 
nucleotide hydrolase within the cell.  Nevertheless, the frbI gene in the extended FR-900098 
cluster was found to encode a nucleotide hydrolase as well, and was demonstrated to convert 
CMP-5’-FR-900098 to FR-900098.  Finally, a possible function for FrbJ was demonstrated in 
vitro in the conversion of FR-900098 to FR-33289, a derivative first reported by Okuhara and 
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co-workers at the same time that FR-900098 was originally identified [38].  However, in vivo 
production of this compound was not detected. 
 
1.2.2.4 Total synthesis 
The first efforts toward the total synthesis of fosmidomycin and FR-900098 were undertaken by 
researchers at the Fujisawa Chemical Co., Ltd. at the time of their original isolation [37].  In this 
case, the goal of the syntheses was to confirm the predicted chemical structures of the two novel 
compounds, and so economics and scale were not priorities.  Nevertheless, both compounds were 
successfully synthesized in three steps.  First, 3-(N-tosyl-N-benzyloxyamino)propyl bromide was 
coupled to sodium diethylphosphonate through a Michaelis-Becker reaction.  Second, the 
product was hydrolyzed in concentrated HCl-AcOH to give the hydroxylamine.  Finally, the 
complete FR-900098 or fosmidomycin were obtained through acylation with Ac2O/H2O or 
acetic-formic anhydride, respectively. 
 
Although syntheses of certain fosmidomycin and FR-900098 derivatives were pursued in 
subsequent years (see next section), total synthesis of the parent compounds themselves was not 
revisited until 2007, when two new reaction schemes were proposed [57, 58].  The method of 
Perruchon and co-workers featured as its initial step a one-pot conversion of acrolein to N-
(benzyloxy)-N-(3-iodopropyl)acetamide through the sequential addition of several components.  
The C-P bond is then installed through reaction with dibenzyl phosphonate, yielding tribenzyl-
protected FR-900098.  Finally, hydrogenolytic removal of the protecting groups gives the final 
product.  In contrast, the method of Fokin and co-workers begins with a nitroso-ene reaction 
between commercially available diethyl allylphosphonate and in situ-prepared nitrosocarbonyl 
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methane to yield the unsaturated diethyl ester derivative of FR-900098.  Hydrogenation then 
gives the diethyl ester derivative, which can be converted to FR-900098 through subsequent ester 
hydrolysis and partial neutralization.  Alternatively, dibenzyl allylphosphonate can be utilized as 
the starting reagent.  In this case, the product of the nitroso-ene reaction can be converted 
directly to the final product through hydrogenation and neutralization, although in lower overall 
yield. 
 
1.2.2.5 Synthesis of analogs and derivatives 
While fosmidomycin and FR-900098 have been demonstrated to be potent antimalarial 
compounds, the fact remains that they are not optimized for use as human therapeutics.  As a 
result, several efforts have been directed toward the synthesis of a variety of analogs and 
derivatives, both in a search for greater efficacy and to facilitate structure-activity relationship 
(SAR) studies.  The earliest of these was again carried out by researchers at the Fujisawa 
Chemical Co., Ltd. [59].  Through their synthetic efforts, they were able to generate four 
different types of compounds: fosmidomycin and FR-900098 with an additional hydroxyl group 
on the β-carbon; 1-trans-propenyl analogs of both compounds; ethylene analogs of both 
compounds, containing only a two-carbon spacer; and methylphosphinic acids of both 
compounds.  As the antimalarial capabilities of this class of compounds had not been established, 
they were instead assayed against a broad spectrum of microbes for antibiotic behavior.  
Although some of the derivatives showed minor improvements against particular species, 
fosmidomycin was again found to be the most potent overall antibiotic.  As a result, interest in 
synthesis of derivatives and analogs remained minimal for the next several years.  One 
exception, however, is the work of Öhler and Kanzler, who in 1995 published an alternate 
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synthetic route to the 1-trans-propenyl analogs [60].  Through subsequent hydrogenation, the 
corresponding propylphosphonates could be generated for further derivitization. 
 
With the discovery of fosmidomycin and FR-900098 as potent antimalarials and subsequent 
clinical trials, interest in derivative synthesis boomed.  Among the goals of these efforts was 
improvement of the 20 – 40% bioavailability observed for fosmidomycin [61].  To this end, 
multiple syntheses of ester prodrugs were reported (Figure 1.6a).  These derivatives were 
designed to increase uptake by masking the charged phosphonate moiety until the compounds 
enter the bloodstream, at which point ubiquitous esterases release the active drug.  In 2001, 
Reichenberg and co-workers synthesized three diaryl ester prodrugs of FR-900098: the diphenyl 
ester, the bis-(2-methyl-phenyl) ester, and the bis-(4-methoxy-phenyl) ester [62].  Of these, oral 
administration of the diphenyl ester was found to be more effective than oral FR-900098 in the 
P. vinckei mouse model, while oral administration of the bis-(4-methoxy-phenyl) ester was most 
effective, performing comparably to intraperitoneally dosed FR-900098.  However, concern over 
the toxicity of the phenol product of ester bond cleavage led to the exploration of alternate alkyl 
masking groups.  Synthesis of a variety of acyloxyalkyl prodrugs and evaluation in the P. vinckei 
mouse model revealed the pivaloyloxymethyl, acetyloxyethyl, and propionyloxyethyl esters to be 
more effective than FR-900098.  Additionally, evaluation of plasma concentrations of FR-
900098 after dosage confirmed the improved bioavailability of the acetyloxyethyl ester [63].  In 
a follow-up study, alkoxycarbonyloxy esters were also synthesized and evaluated [64].  Both the 
methoxycarbonyloxyethyl and ethoxycarbonyloxyethyl esters were found to be more effective 
than FR-900098.  Single ester prodrugs were also synthesized and evaluated, as these crystalline 
compounds would lend themselves more easily to capsule formulation than the oily diester 
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compounds.  However, no improvement in efficacy over FR-900098 was observed with these 
compounds. 
 
The next area of derivitization to be explored in depth was substitution on the α-carbon (Figure 
1.6b), with several examples published within the last five years [65-69].  The van Calenbergh 
group, for example, explored a variety of substituted phenyl groups in the α-position and assayed 
them both against purified E. coli Dxr and two P. falciparum strains.  Curiously, none of the 
derivatives proved to be better inhibitors of E. coli Dxr than fosmidomycin or FR-900098, but 
three of the compounds (one fosmidomycin derivative and two FR-900098 derivatives, each 
featuring chlorine substituents on the phenyl moiety) did show significant improvement in IC50 
against one or both of the P. falciparum strains.  The Kurz group similarly tested a series of 
arylmethyl fosmidomycin and FR-900098 derivatives against P. falciparum, also including 
pivaloyloxymethyl ester protecting groups on the phosphonate.  Although they were able to 
identify one compound (containing a 3,4-dichlorobenzyl substituent) with improved activity 
when compared to the fosmidomycin prodrug, none of their analogs could outperform the FR-
900098 prodrug.  Finally, a different study by Kurz and co-workers looked at various alkyl 
substitutions at the α-position of the pivaloyloxymethyl ester prodrugs.  It was found that ethyl, 
propyl, isopropyl, and dimethyl substitutions significantly decreased antimalarial efficacy, while 
methyl substitution produced a compound of comparable antimalarial activity to the FR-900098 
prodrug.  Some substituted phenyl derivatives were also included in this study, with results 
similar to those described above.  More recently, the van Calenbergh group examined 
halogenation at the α-position.  Substitution of FR-900098 with fluorine or chlorine was 
analyzed by growth inhibition of P. falciparum and in the P. berghei mouse model.  Both 
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compounds performed comparably to FR-900098 in P. falciparum inhibition, and the fluorinated 
derivative performed better in the in vivo trial. 
 
Beyond just α-substituted carbon spacers, cyclized and unsaturated derivatives have also been 
synthesized and analyzed for antimalarial efficacy.  Another study from the van Calenbergh 
group looked at cyclopropyl fosmidoycin and FR-900098 derivatives, restricting rotational 
freedom of the spacer by bridging the α- and β-carbons [70].  Unfortunately, none of the 
derivatives synthesized could outperform FR-900098 in inhibition of E. coli Dxr or P. 
falciparum growth.  Similarly, incorporation of the three-carbon spacer into a cyclopentane ring 
failed to match the inhibition levels of fosmidomycin and FR-900098 toward E. coli Dxr [71].  
Finally, synthesis of α,β-unsaturated derivatives with a variety of α-aryl substitutions was carried 
out, but the resulting compounds were all significantly worse inhibitors of E. coli Dxr [72]. 
 
Among the most recent attempts at the synthesis of novel derivatives are the β- and γ-oxa 
isosteres and the so-called “reverse analogs,” replacing the N-terminal moiety with a reversed 
hydroxamic acid group (Figure 1.6c).  Of the β- and γ-oxa isosteres synthesized, γ-oxa 
substitution was found to significantly reduce activity, while β-oxa substitution of FR-900098 or 
the N-methyl hydroxamate reverse analog yielded slightly better inhibitors of P. falciparum 
growth [73].  Alternatively, the Kurz group synthesized the α-phenyl-substituted hydroxamate 
and N-methyl hydroxamate FR-900098 reverse analogs, revealing the latter to be a particularly 
potent inhibitor of P. falciparum and its recombinant Dxr enzyme [74].  The α-fluorinated N-
methyl hydroxamate reverse analog was also found to have high antimalarial activity when 
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assayed in the P. berghei mouse model, further illustrating the promise of reverse analogs as 
more potent antimalarials [69]. 
 
1.3 Conclusions 
Although worldwide efforts to stop malaria have proceeded for several decades, the disease 
remains to this day a significant global health issue that threatens half of the world’s population.  
In recent years, the spread of the disease has been held in check, primarily through the 
distribution of insecticide-treated bed nets, residual insecticide spraying, and the development of 
artemisinin-based combination therapies.  Nevertheless, new drugs are still needed to combat the 
ever-present threat of microbial drug resistance.  Phosphonic acids, an under-utilized class of 
natural products, may prove to be a valuable ally in this fight. 
 
Fosmidomycin and its N-acetyl analog FR-900098, though first discovered in 1980, have only in 
the past decade shown their potential as highly effective antimalarial drugs.  As Streptomycete 
natural products, however, these compounds are by no means optimized as human therapeutics.  
Thus, through the synthesis of a variety of derivatives, it may be possible to identify even more 
potent antimalarials.  With the recent elucidation and heterologous expression of the FR-900098 
biosynthetic pathway, the possibility to generate new derivatives through protein engineering, 
metabolic engineering, and combinatorial biosynthesis is opened, allowing access to novel 
derivatives difficult to access by synthetic means. 
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1.5 Figures 
 
Figure 1.1: Global scope of malaria from 1900 to the present, from ref. 3. 
24 
 
 
Figure 1.2: Chemical structures of some of the most widely-used antimalarial drugs. 
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Figure 1.3: A selection of naturally occurring phosphonate compounds with interesting 
bioactivities. 
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Figure 1.4: The biosynthetic pathway of FR-900098, adapted from ref. 5. 
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Figure 1.5: Overview of synthetic strategies for FR-900098 production from (a) Kamiya et al. 
(ref. 36), (b) Perruchon et al. (ref. 57), and (c) Fokin et al. (ref. 56).  For complete reaction 
details, refer to the respective manuscripts. 
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Figure 1.6: Overview of FR-900098 derivatives explored as potential antimalarial drugs.  (a) 
Ester protecting groups found to increase the antimalarial efficacy of FR-900098.  (b) 
Substitutions at the α position with significantly improved antimalarial activity compared to FR-
900098.  (c) Potent reverse analogs of FR-900098, including the β-oxa reverse analog with 
pivaloyloxymethyl ester protecting groups and two α-substituted compounds. 
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Chapter 2: Characterization of the N-Acetyltransferase FrbF from 
the FR-900098 Biosynthetic Pathway 
 
2.1 Introduction 
The FR-900098 biosynthetic pathway from Streptomyces rubellomurinus has been well studied 
in the heterologous hosts Streptomyces lividans and Escherichia coli through the collaborative 
efforts of the Kelleher, Metcalf, and Zhao groups at the University of Illinois at Urbana-
Champaign [1, 2].  As a result, the specific biochemical transformations catalyzed by each 
enzyme in the pathway have been established, laying the groundwork for both the 
overproduction of FR-900098 in a heterologous host and for the combinatorial biosynthesis of 
novel FR-900098 derivatives.  The latter aim can be achieved through two distinct means: 
introduction of novel enzyme(s) from different pathways into the native biosynthetic framework, 
or retooling of the native biosynthetic enzymes to introduce novel functionalities.  Both of these 
approaches have been successfully demonstrated in the literature.  For example, McDaniel and 
co-workers applied the first approach to synthesize several derivatives of the polyketide natural 
product erythromycin through the substitution of polyketide synthase (PKS) domains from the 
rapamycin biosynthetic gene cluster [3].  Bernhardt and co-workers, on the other hand, applied 
the second approach, using a novel colorimetric screening method to broaden the substrate 
specificity of strictosidine synthase (STS) from Catharanthus roseus [4].  As a result, they were 
able to synthesize new indole alkaloid derivatives not accessible via the native pathway. 
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The focus of the work described here is to apply the latter approach to the biosynthetic pathway 
of FR-900098 for the synthesis of novel derivatives.  To this end, the N-acetyltransferase FrbF 
was selected as the target for kinetic and structural characterization as well as directed evolution 
for multiple reasons.  First of all, FrbF catalyzes the penultimate step of FR-900098 biosynthesis, 
followed only by nucleotide cleavage to give the final product.  As a result, none of the upstream 
pathway intermediates will be altered in the context of a mutated FrbF, indicating that all of the 
upstream enzymes will still be able to function normally.  Mutating an enzyme further upstream 
in the pathway, in contrast, would yield a series of altered pathway intermediates.  Given the 
high substrate specificity observed for some of the pathway enzymes, such as the bifunctional 
nucleotide transferase/decarboxylase FrbH, this could significantly slow or completely halt the 
biosynthesis of any novel derivatives.  The only enzyme downstream of FrbF, the nucleotide 
hydrolase FrbI, exhibits very broad substrate specificity, and thus would likely be unaffected by 
the introduction of any FrbF mutant.  Further, even in the absence of FrbI, ubiquitous nucleotide 
hydrolases within the cell can also serve to catalyze the final step.  Second, although numerous 
derivatives of FR-900098 have been synthesized as described in the previous chapter, variation 
in the N-acyl substituent remains largely unexplored, with only the naturally produced N-formyl 
(fosmidomycin) and N-acetyl (FR-900098) moieties typically considered.  Moreover, variation at 
this end of the molecule is tolerated and can lead to more potent Dxr inhibitors, as exemplified 
by the N-methyl hydroxamate “reverse analogs” described in Chapter 1.  Third, although FrbF 
demonstrates activity analogous to enzymes of the well-studied GCN5-like N-acetyltransferase 
(GNAT) superfamily, FrbF shares no sequence similarity with any members thereof.  Rather, 
FrbF shares sequence similarity with a number of uncharacterized, putative aminoglycoside 
N(3’)-acetyltransferases.  As a result, characterization of FrbF could grant useful biochemical 
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insights into a new class of N-acetyltransferases, and could facilitate further studies of new 
uncharacterized secondary metabolite pathways. 
 
The previous research efforts of Ty Johannes and Matt DeSieno in the Zhao group have 
demonstrated that FrbF exhibits activity only toward cytidine monophosphate-conjugated 
substrates [2].  Further, they concluded that FrbG-catalyzed hydroxylation precedes FrbF-
catalyzed acetylation, as in vitro analysis of purified FrbG shows no activity toward the N-
acetylated substrate, CMP-5’-N-acetyl-3-aminopropylphosphonate (CMP-5’-Ac3APn).  FrbF, 
however, was found to catalyze acetylation of either the primary amine substrate, CMP-5’-3-
aminopropylphosphonate (CMP-5’-3APn), or the hydroxylamine substrate, CMP-5’-N-hydroxy-
3-aminopropylphosphonate (CMP-5’-H3APn).  Interestingly, FrbF was observed to more readily 
catalyze acetylation of the primary amine than the hydroxylamine.  This is a surprising finding in 
the context of the biosynthetic pathway, given that CMP-5’-H3APn is the true substrate for FR-
900098 synthesis, and also biochemically, as the hydroxylamine moiety would be expected to be 
more reactive toward alkylation.   
 
Here, it is our goal to confirm the qualitative studies previously performed with FrbF by alternate 
methods, and further to quantify the kinetic behavior of this enzyme with its native substrates.  
Additionally, thorough analysis of the active site will be applied to elucidate the catalytic 
mechanism of this enzyme.  Finally, the substrate specificity of the wild type enzyme will be 
explored with respect to its acyl-donor to inform future directed evolution efforts targeting the 
substrate specificity of FrbF for biosynthesis of novel FR-900098 derivatives. 
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2.2 Results and Discussion 
2.2.1 Kinetics characterization with phosphonate substrates 
2.2.1.1 CMP-5’-3APn synthesis and kinetics 
Although the FR-900098 biosynthetic pathway has been definitively demonstrated to proceed via 
N-hydroxylation followed by N-acetylation [2], FrbF is nevertheless able to acetylate both the 
primary amine substrate CMP-5’-3APn and the hydroxylamine substrate CMP-5’-H3APn 
(shown in Figure 2.1a).  As a result, CMP-5’-3APn was enzymatically synthesized using FrbH 
and purified for kinetic assays.  Kinetic parameters with CMP-5’-3APn have previously been 
reported using a continuous assay with 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB), but 
numerous efforts to replicate these results under identical conditions proved unsuccessful.  This 
is most likely due to the limited sensitivity of DTNB-based quantitation, especially given the low 
activity level of FrbF.  Further, DTNB can react with the protein itself, increasing the noise level.  
As a result, alternate methods were pursued to definitively ascertain the correct kinetic 
parameters. 
 
The two methods considered for measuring kinetics were an enzyme-coupled assay with α-
ketoglutarate dehydrogenase, in which the free CoA product of FrbF catalysis is rapidly 
converted to succinyl-CoA by α-ketoglutarate dehydrogenase with concomitant reduction of 
NAD
+
, and an HPLC-based assay, in which the CMP-conjugated product can be directly assayed 
at a UV absorbance wavelength of 254 nm.  Evaluation of both methods found HPLC-based 
quantitation to have a much better signal-to-noise ratio, and so this method was chosen for 
subsequent assays.  Surprisingly, linear dependence on substrate concentration was observed far 
beyond the Km value of 35 µM previously reported, ultimately yielding a Km value of 391 µM 
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with a kcat value of 2.042 min
-1
 (Table 2.1).  Given that CMP-5’-3APn is not the native substrate for 
FrbF, however, it is not surprising to see this relatively low level of activity.  Further evaluation of the 
enzyme with the His6 tag at the C-terminal position or with the N-terminal His6 tag removed via 
thrombin cleavage did not show significantly altered activity (data not shown). 
 
2.2.1.2 CMP-5’-H3APn, the native phosphonate substrate for FR-900098 production 
The native substrate for FR-900098 synthesis, CMP-5’-H3APn, can be synthesized in vitro using 
the purified FrbH and FrbG enzymes.  However, numerous efforts to observe FrbF catalysis with 
the purified reaction product revealed no reproducible activity.  Subsequent LC-MS analysis of 
the purified substrate revealed a dominant signal corresponding to a parent ion m/z of 457 in 
negative mode, with only a minimal signal at the expected m/z of 459.  It was then proposed that 
the m/z = 457 signal comes from the nitroso derivative CMP-5’-NO3APn, which could 
potentially be formed via a second hydroxylation of the hydroxylamine to the dihydroxy 
intermediate, followed by a spontaneous dehydration. 
 
Two schemes were proposed for the oxidation of the hydroxylamine to the nitroso.  First, the 
hydroxylamine could become a surrogate substrate for FrbG and pass through a second catalytic 
cycle, yielding the nitroso after spontaneous dehydration.  Second, the hydroxylamine could 
simply undergo a non-enzymatic oxidation, either through reaction with oxygen or through a 
disproportionation reaction with another hydroxylamine molecule.  To study the first possibility, 
the FrbG reaction was monitored over time by LC-MS, and the signals for the substrate and both 
products were followed with time.  In this case, we would expect to see an initial formation of 
the hydroxylamine, followed by consumption of this compound and a lagging increase in 
34 
 
formation of the nitroso.  However, concomitant formation of both compounds was observed, 
even at the earliest time points assayed, indicating that the second possibility may be at play. 
 
To further study the second possibility, two methods were pursued.  First, the FrbG reaction was 
run for a specified amount of time, after which the enzyme was removed by diafiltration.  
Subsequently, the filtered reaction mixture was incubated at a constant temperature and 
periodically analyzed by LC-MS.  At 30 °C, rapid loss of the hydroxylamine compound was 
observed, with half of the sample depleted in ~90 min (Figure 2.2a).  Even at 5 °C, the m/z = 459 
signal was completely lost from the LC-MS trace following overnight incubation.  To 
corroborate this observation, attempts were made to purify the hydroxylamine from FrbG 
reaction mixtures, but this could not be achieved.  Instead, the nitroso compound was purified 
and subsequently reduced back to the hydroxylamine under anaerobic conditions using samarium 
diiodide.  Following anaerobic incubation for several hours, little reformation of the nitroso was 
observed by LC-MS.  Once exposed to air, however, rapid reformation occurred, with the 
hydroxylamine signal almost completely lost after 30 min (Figure 2.2b).  Thus, it can be 
concluded that the conversion of the hydroxylamine to the nitroso is a rapid non-enzymatic 
process, as has been observed previously for other hydroxylamine compounds [5]. 
 
To assess the kinetic behavior of FrbF with this substrate, in situ generation via concomitant 
FrbG catalysis was attempted.  Interestingly, incubation of equimolar amounts of FrbF and FrbG 
showed no significant difference in FrbF activity, both via HPLC analysis and DTNB endpoint 
assay.  This is likely due to the fact that even though FrbG can supply the true hydroxylamine 
substrate for FrbF, both enzymes can also compete for the primary amine substrate, and some of 
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the hydroxylamine can be lost to the non-reactive nitroso.  Increasing the FrbG concentration, 
however, led to an increase in observed FrbF activity, up to a 10:1 molar ratio of FrbG to FrbF.  
Beyond this ratio, FrbF activity did not increase further.  Given the same initial concentration of 
FrbF, the observed activity level of FrbF increased 6.7-fold when supplemented with a 10-fold 
molar excess of FrbG.  This indicates that FrbF does in fact show greater activity with CMP-5’-
H3APn than CMP-5’-3APn, which correlates with its understood role in FR-900098 
biosynthesis.  
 
2.2.2 Kinetics characterization with coenzyme A substrates 
2.2.2.1 Acetyl-CoA, the native acetyl donor for FR-900098 production 
For the biosynthesis of FR-900098, FrbF installs an acetyl moiety on the hydroxylamine 
substrate by transferring the respective functional group from acetyl-CoA.  To determine the 
kinetic parameters with respect to this substrate, we employed the HPLC-based assay described 
above.  In this case, the CMP-5’-3APn surrogate substrate was used to ensure that the 
concentration of this substrate remained constant from trial to trial.  Kinetic characterization with 
acetyl-CoA reveals a 20-fold lower Km value than that observed for the CMP-5’-3APn substrate.  
This is likely due to the significant number of favorable contacts that the enzyme can form with 
this rather large substrate molecule in its binding cleft, as will be described in the Section 2.2.3.1.  
The kcat observed with acetyl-CoA is approximately 55 % of the kcat observed for CMP-5’-3APn.  
This is a reasonable observation given that the acetyl-CoA kinetic parameters were measured 
with the CMP-5’-3APn concentration near its Km value, at which point half of the maximum rate 
would be expected. 
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2.2.2.2 Evaluation of alternate acyl-CoAs 
As described above in the Introduction section, it is our goal not only to characterize the 
behavior of FrbF toward its native substrates, but also to determine the scope of acyl-donor 
substrates that it will accept for the synthesis of novel N-acylated FR-900098 derivatives.  In the 
literature, substrate specificity varies significantly between different acyltransferase enzymes.  
For example, Walker and co-workers studied the N-benzoyltransferase from Taxus cuspidata, 
which is involved in Taxol biosynthesis [6].  They assayed this enzyme with its native substrate, 
benzoyl-CoA, as well as the similar analog phenylacetyl-CoA and dissimilar analog acetyl-CoA, 
but only saw product formation with the native substrate.  In contrast, Morell and co-workers 
studied the relative activity of N-acyltransferases involved in ceramide biosynthesis isolated 
from mouse brain microsomes [7].  Although the highest activity was observed toward stearoyl-
CoA, lower activity was also observed toward lignoceroyl-CoA, palmitoyl-CoA, and oleoyl-
CoA, at a ratio of 60:12:3:1, respectively.  More recently, Magalhaes and Blanchard studied the 
AAC(3)-IV aminoglycoside acetyltransferase from E. coli, which is involved in antibiotic 
resistance [8].  They looked at the shorter acyl-donors acetyl-, propionyl-, malonyl-, and butyryl-
CoA, and determined kinetic constants for all four.  Interestingly, acetyl- and propionyl-CoA 
showed similar kcat values, but a difference in Km of ~6-fold in favor of acetyl-CoA.  Extending 
the chain further, propionyl- and malonyl-CoA showed indistinguishable Km values, but a 3.7-
fold difference in kcat in favor of propionyl-CoA.  Butyryl-CoA was by far the least preferred 
substrate, with both the highest Km and lowest kcat.  Finally, as an example of substrate 
promiscuity, Killenberg and Jordan showed approximately equivalent Km and Vmax values for the 
bile acid-CoA:amino acid N-acyltransferase from rat liver toward four different bile acid-CoA 
substrates [9]. 
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For our studies, we wanted to determine the breadth of substrate promiscuity exhibited by FrbF 
toward its acyl-donor.  As a result, seven alternate acyl-CoAs were selected for relative activity 
assays, including propionyl-, isobutyryl-, β-hydroxybutyryl-, acetoacetyl-, malonyl-, succinyl-, 
and glutaryl-CoA (Figure 2.1b).   These substrates were selected to gradually expand the size of 
the acyl substituent, such that only small changes to the FR-900098 scaffold will be made.  
Additionally, these acyl-CoA substrates are biologically relevant, and their overproduction could 
potentially be engineered in future host strains for the overproduction of specific FR-900098 
derivatives. 
 
Activity assays with alternate acyl-CoA substrates were first carried out using the DTNB-based 
assay method.  However, low activity levels and competing non-enzymatic hydrolysis of the 
acyl-CoA thioester bonds hindered accurate determination of activity, and so HPLC-MS analysis 
was instead employed.  Initial analyses showed no detectable activity by UV absorbance or MS 
for glutaryl-CoA, which is not surprising given that this was the largest acyl substituent 
evaluated.  Surprising, however, was the absence of detectable activity for β-hydroxybutyryl-
CoA, given that activity could be detected for the similar acetoacetyl- and malonyl-CoA 
substrates.  This suggests that the second carbonyl moiety not present in β-hydroxybutyryl-CoA 
may be necessary for favorable interactions with the active site to support catalysis.  Of the other 
substrates evaluated, both isobutyryl- and succinyl-CoA showed activity by MS analysis, as 
indicated by the presence of the expected m/z parent ion with the corresponding m/z = 322 
daughter ion due to loss of CMP.  However, no detectable UV peak was observed for either of 
these two products, preventing accurate quantitation of relative activity toward these novel 
substrates.  Propionyl-, malonyl-, and acetoacetyl-CoA all showed activity both by UV 
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absorbance and MS analysis (Figure 2.3).  As a result, activity levels were measured for each of 
these substrates relative to acetyl-CoA.  Additionally, kinetic parameters were determined for 
propionyl-CoA, which exhibited the highest relative activity.  This is not surprising, given that 
the propionyl moiety is the most similar to the acetyl moiety. 
 
Interestingly, the Km value obtained for propionyl-CoA is approximately the same as that 
obtained for acetyl-CoA.  This likely indicates that binding of the acyl-CoA substrate relies 
predominantly on interactions with the CoA backbone itself, and not with the acyl functionality.  
The ~12-fold drop in kcat for this substrate relative to acetyl-CoA, then, is most likely caused by 
the increased steric hindrance introduced by the bulkier acyl chain, which could potentially block 
the amine or hydroxylamine of the substrate from attacking the thioester carbonyl.  This is 
further evinced by the decreasing activity observed with the bulkier malonyl-CoA (2.7 % relative 
activity) and acetoacetyl-CoA (0.4 % relative activity), and the lack of quantifiable activity 
observed when the isobutyryl-CoA or succinyl-CoA substrates are utilized. 
 
2.2.3 Elucidation of the structure and catalytic mechanism 
2.2.3.1 Analysis of the crystal structure 
The x-ray crystal structure of FrbF in complex with acetyl-CoA was solved in collaboration with 
Brian Bae of Satish Nair’s group at the University of Illinois, Urbana-Champaign.  As 
anticipated based on the lack of sequence similarity, FrbF shares no structural similarity to 
members of the GNAT superfamily of enzymes.  Instead, the most similar structural homologs 
are the proteins YokD from Bacillus subtilis and BA2930 from Bacillus anthracis, both of which 
are biochemically uncharacterized.  Querying the GenBank database reveals several other 
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uncharacterized gene sequences, mostly from Bacillus.  As the functions of these genes are as yet 
undetermined, it is possible that they too could be involved in the synthetic pathways of 
heretofore undiscovered secondary metabolites. 
 
The overall structure of FrbF is comprised of a large domain and a small domain connected by 
multiple linkers without secondary structure (Figure 2.4a).  This forms a significant cleft into 
which the acetyl-CoA molecule is aligned.  At the adenosine end of the molecule, a hydrophobic 
pocket composed of Leu-48, Trp-53, and Val-54 interacts favorably with the adenine ring.  
Additionally, hydrogen bonds are formed with residue Arg-19 and the backbone carbonyls of 
Gly-52 and Val-54.  Further favorable interactions are formed between the phosphopantetheine 
arm and residues Ser-188 and His-45.  Finally, multiple polar residues are located in the vicinity 
of the acetyl-group thioester, the catalytic relevance of which will be explored in the next 
section.  Adjacent to the acetyl-CoA binding cleft is another site where the CMP-conjugated 
phosphonate substrate is likely to bind (Figure 2.4b).  Although the co-crystallized structure with 
this substrate was not obtained, it is likely that basic residues within this region help to favorably 
interact with the diphosphate motif.  This type of interaction would also help to explain the 
absence of FrbF activity observed toward the non-CMP-conjugated 3APn substrate in previous 
studies. 
 
2.2.3.2 Mutational analysis of the active site 
In order to elucidate the catalytic mechanism of FrbF, the residues located within 6 Å of the acyl 
moiety of the bound acetyl-CoA were analyzed (Figure 2.5).  In principle, one could expect the 
reaction mechanism to proceed either via direct attack of the amine or hydroxylamine substrate 
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on the carbonyl group of acetyl-CoA, as has been observed for the majority of GNAT 
superfamily members, or via an acyl-enzyme intermediate, as demonstrated in the yeast histone 
acetyltransferase Esa1 and in multiple mycobacteria [10, 11].  Of the residues present in the 
active site, Glu-187, Ser-188, Thr-190, and Glu-231 were identified as possible general acids, 
while only His-193 was identified as a potential general base.  Alanine mutants at each of these 
five positions were created, and their relative activities were measured in comparison to the wild 
type enzyme (Figure 2.6).  The results indicate that the Glu-187Ala and Glu231Ala mutants 
demonstrate activities similar to the wild-type enzyme, confirming that these two residues do not 
play a role in catalysis and further ruling out mechanisms that require formation of a covalent 
acyl intermediate with an active site carboxylate.  The Ser-188Ala mutant exhibited a modest 
decrease in activity, as anticipated based on its interaction with the phosphopantetheine arm of 
the acetyl-CoA substrate.  In contrast, the activity of the His-193Ala mutants was less than 1% 
of that of the wild-type, and no activity could be observed for the Thr-190Ala mutant.  These 
results strongly suggest the involvement of Thr-190 and His-193 in acid/base chemistry during 
acetyl-group transfer.  These results are consistent with the mechanistic route proposed in Figure 
2.7.  Following the binding of the substrate conjugate CMP-5’-3APn and acetyl donor acetyl-
CoA at the active site, His-193 functions as a general base to facilitate the attack of the amine or 
hydroxylamine on the electrophilic carbonyl of the acetyl group.  Protonation of the resultant 
tetrahedral intermediate results in its collapse to yield the hydroxamate and CoA.  Alternatively, 
it is worth noting that His-193 could instead serve to stabilize the tetrahedral intermediate, as the 
N-O distance varies from 2.9 Å to 4.2 Å between the two pairs of FrbF dimers. 
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Further analysis was carried out at the Thr-190 position through mutations to both Ser and Cys, 
as well as mutation of His-45 to Ala.  His-45 is the nearest residue to Thr-190, and so we 
speculated that this residue might serve to activate Thr-190 for a novel reaction mechanism 
involving attack of Thr-190 on the carbonyl of the acetyl group to form an acyl-enzyme 
intermediate.  The His-45Ala mutation reduced the relative activity of FrbF to 1.5% of the 
wild type, supporting the catalytic relevance of this residue.  However, high-resolution mass 
spectrometry provided no evidence of an acyl-enzyme intermediate (data not shown).  Further 
analysis of the crystal structure suggests that His-45 can participate in hydrogen bonding 
interactions both with a carbonyl group of the acetyl-CoA phosphopantetheine arm and with the 
backbone amide nitrogen of either Thr-190 or Ser-191, suggesting that this residue is critical for 
the positioning of acetyl-CoA and the catalytically requisite Thr-190 residue.  Further, the Thr-
190Cys mutation, which would more closely reflect the active site of NAT enzymes that 
utilize an acyl-enzyme intermediate, lowered the activity dramatically, discrediting the prospect 
of a novel, Thr-mediated ping pong mechanism.  Finally, the Thr-190Ser mutation had no 
detectable effect on the relative activity. 
 
2.3 Conclusions and Outlook 
In this study, we structurally and biochemically characterized the N-acetyltransferase FrbF from 
the FR-900098 biosynthetic cluster.  Kinetic parameters were determined with acetyl-CoA, the 
native acyl-donor, and CMP-5’-3APn, a surrogate phosphonate substrate.  Additionally, we 
identified a rapid, non-enzymatic oxidation of the native hydroxylamine substrate, CMP-5’-
H3APn, to its nitroso derivative.  Although this prevented the measurement of kinetic parameters 
with this substrate, we nevertheless demonstrated via in situ generation of CMP-5’-H3APn that 
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this compound is in fact the preferred substrate for FrbF, both through HPLC analysis and a 
chemically-coupled assay.  Further, we demonstrated that FrbF exhibits reasonably high 
substrate specificity for acetyl-CoA as its acyl-donor, as relative activity levels fell significantly 
with increasing substrate size.  For propionyl-CoA, this was due predominantly to a decrease in 
kcat, indicating that it is likely hindrance of attack by the nucleophilic substrate, and not of 
binding, that lowers activity with novel acyl-donors.  Finally, we employed a site-directed 
mutagenesis approach to elucidate the roles of key active site residues in catalysis. 
 
The knowledge gained here will be useful in the development of new FR-900098 derivatives.  
Understanding of the kinetic behavior of FrbF will aid in the selection of appropriate screening 
conditions for novel FrbF substrates.  Moreover, by studying the acyl-donor scope of wild type 
FrbF, we can better select target substrates for future directed evolution studies.  With knowledge 
of the crystal structure, too, we can more rationally target our directed evolution approach to 
specific residues that may be involved in limiting the acyl-donor size, while leaving intact the 
residues necessary for catalysis.  Finally, characterization of this representative of a new class of 
N-acetyltransferases may facilitate future studies of previously uncharacterized members of this 
family, which could lead to the discovery of new and interesting secondary metabolite gene 
clusters. 
 
2.4 Materials and Methods 
2.4.1 Materials 
The Escherichia coli cloning strain DH5α, expression strain BL21(DE3) and the expression 
vector pET28a were obtained from EMD Biosciences (San Diego, CA).  Kanamycin and 
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isopropyl-β-D-1-thiogalactopyranoside (IPTG) were purchased from Gold Biotechnology (St. 
Louis, MO).  All chemicals, including reaction buffers and the reagents samarium diiodide, 
cytidine triphosphate (CTP), 2-amino-4-phosphonobutyrate (2APn), and all acyl-CoAs, were 
purchased from Sigma-Aldrich (St. Louis, MO) except for the co-factor NADPH, which was 
purchased from Applichem (Darmstadt, Germany), and organic solvents, which were purchased 
from Thermo-Fisher Scientific (Pittsburgh, PA).  All PCR reagents and restriction enzymes were 
purchased from New England Biolabs (Ipswich, MA), and DNA Miniprep and Gel Purification 
Kits were purchased from Qiagen (Valencia, CA).  All primers were synthesized by Integrated 
DNA Technologies (Coralville, IA).  Talon Cobalt immobilized metal affinity chromatography 
(IMAC) resin was purchased from Clontech Laboratories (Mountain View, CA).  All other 
materials were purchased from Thermo-Fisher Scientific. 
 
2.4.2 Protein expression and purification 
The E. coli BL21(DE3) strains containing pET28a-FrbF, pET28a-FrbG, and pET28a-FrbH were 
previously prepared via ligation of the respective ORFs between the NdeI and HindIII restriction 
sites.  Cells were grown in Terrific Broth (TB) media supplemented with kanamycin (50 μg/mL) 
at 37 °C to an OD600 of ~0.8, after which induction was carried out by addition of 0.3 mM IPTG 
at 25 °C.  In the case of FrbH, IPTG induction was accompanied by addition of 50 µg/mL 
pyridoxal-5’-phosphate (PLP).  After 18 hr, the cells were harvested by centrifugation at 7500 
rpm for 15 min and resuspended in 20 mM Tris-HCl (pH 7.65), 0.5 M NaCl, and 15 % glycerol 
supplemented with 1 mg/mL lysozyme.  After a freeze-thaw cycle at -80 °C, the cell suspension 
was sonicated to ensure sufficient lysis.  The lysate was clarified multiple times by centrifugation 
at 15000 rpm for 15 min, after which the His6-tagged proteins were purified by affinity 
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chromatography on TALON Superflow Co
2+
 resin coupled to fast-performance liquid 
chromatography.  The eluted proteins were washed three times in 50 mM HEPES (pH 7.25), 
concentrated, and stored in 15 % glycerol at -80 °C. 
 
2.4.3 Generation of FrbF mutants 
FrbF amino acid candidates for mutation were visualized using Molecular Operating 
Environment software (Chemical Computing Group, Montreal, Canada).  Mutants of the FrbF 
enzyme were generated by the megaprimer PCR method.  Briefly, primers were designed at the 
site of interest containing the desired mutation such that a larger primer (a “megaprimer”) 
containing the mutation could be generated by PCR, using the regular forward or reverse primer 
as the second primer (whichever yielded the shortest PCR product).  Next, PCR amplification of 
the full-length mutant gene was carried out using the megaprimer at one end of the gene and the 
regular primer at the opposite end.  Finally, the full length gene containing the mutation was 
digested with NdeI and HindIII and ligated into the correspondingly digested pET28a vector 
backbone.  The ligation product was then used to transform the E. coli cloning strain DH5α.  
Transformants were picked and grown in 5 mL LB + 50 µg/mL kanamycin.  Their plasmids were 
isolated and sequenced by ACGT, Inc. (Wheeling, IL), and Sequencher software (Gene Codes 
Corporation, Ann Arbor, MI) was used to confirm the presence of only the desired mutation.  
The correct plasmids were then used to transform the expression strain E. coli BL21(DE3), and 
frozen stocks of the resultant strains were stored in 15 % glycerol at -80 °C. 
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2.4.4 Preparation of CMP-5’-3APn 
CMP-5’-3APn for kinetic and relative activity assays was synthesized enzymatically using 
purified N-His6-FrbH.  Synthesis was carried out in 50 mM HEPES buffer (pH 7.25) with 1.5 
mM CTP, 3 mM 2APn, 10 mM MgCl2, and ~10 µM FrbH at 30 °C for 4 hr.  Following removal 
of FrbH with a 10 kDa cutoff Amicon centrifugal filter unit (Millipore, Billerica, MA), the 
product was purified by fractionation on an Agilent 1100 Series HPLC (Agilent, Palo Alto, CA) 
using an Alltech Prevail C18 reverse phase column (Grace Davison Discovery Sciences, 
Deerfield, IL) with isocratic flow of 15 mM ammonium formate buffer.  Fractions containing the 
product were pooled, lyophilized, and resuspended in double-distilled water.  The concentration 
of the purified CMP-5’-3APn product was determined by UV absorbance at 254 nm. 
 
2.4.5 CMP-5’-H3APn oxidation assays 
Enzymatic synthesis of CMP-5’-H3APn was performed using purified N-His6-FrbG.  Reactions 
were carried out in 50 mM HEPES buffer (pH 7.25) with 500 µM CMP-5’-3APn, 500 µM 
NADPH, and ~30 µM FrbG at 30 °C for 15 min.  Following removal of FrbG with a 10 kDa 
cutoff Amicon centrifugal filter unit, the product mixture was incubated at 30 °C.  Samples were 
collected at specified time points and kept on dry ice until analysis using an Agilent XCT ion-
trap MSD mass spectrometer at the Roy J. Carver Metabolomics Center (University of Illinois, 
Urbana, IL).  Chemical synthesis of CMP-5’-H3APn was performed using the oxidation product 
CMP-5’-NO3APn, which was purified from FrbG reaction mixtures via HPLC fractionation.  
Reduction of the nitroso to the hydroxylamine was performed anaerobically following the 
method of Kende and Mendoza [12].  In an anaerobic chamber, the lyophilized nitroso 
compound was resuspended in a mixture of tetrahydrofuran (THF) and methanol (95%/5% v/v).  
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To this solution was added a 4-fold molar excess of samarium diiodide in THF.  Following 
agitation for 3 min at  room temperature, the reaction was acidified with 0.1 % trifluoroacetic 
acid and extracted with ethyl acetate.  The product solution was then analyzed by LC-MS both 
before and after aerobic exposure. 
 
2.4.6 Kinetic assays 
All activity assays were performed with N-His6-tagged FrbF in 50 mM HEPES buffer (pH 7.25) 
at 30 °C.  For determination of kinetic parameters, the concentration of one substrate was 
maintained at 400 µM, while the other substrate concentration was varied from 0 – 1000 µM.  
Samples were collected over a 7 minute time course for product quantitation and determination 
of initial rate.  Reactions were initiated with the addition of 1.3 µM FrbF and quenched with 1 % 
trifluoroacetic acid.  All assays were performed in triplicate.  Kinetic parameters were fit to the 
data using nonlinear least-squares regression in OriginPro 8 (OriginLab Corporation, 
Northampton, MA).  Relative activity assays with alternate CoA substrates were performed with 
400 µM CMP-5’-3APn and 200 µM of the CoA compound.  Reactions were initiated with 15 
µM FrbF, and samples were collected over a 60 minute time course.  For substrates for which no 
activity was detected in this time, the assay time was extended up to 12 hr.  For all assays, 
products were detected by UV absorbance at 254 nm on an Agilent 1100 Series HPLC (Agilent, 
Palo Alto, CA), with retention times confirmed using an Agilent XCT ion-trap MSD mass 
spectrometer at the Roy J. Carver Metabolomics Center (University of Illinois, Urbana, IL).  For 
all LC-MS analyses with alternate CoA substrates, product identities were confirmed based on 
detection of the expected m/z parent ion with a corresponding m/z = 322
-
 (CMP) daughter ion in 
the MS/MS profile.  
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2.4.7 Relative activity assays 
Relative activity assays with purified N-His6-tagged FrbF mutants were performed with 400 µM 
CMP-5’-3APn and 200 µM acetyl-CoA over a 7 minute time course.  For those mutants that 
exhibited significantly reduced activity, the assay time was extended up to 60 minutes.  Samples 
were collected and analyzed as described above. 
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2.6 Tables 
Table 2.1: FrbF kinetic parameters (mean ± standard deviation of three independent trials) 
 
substrate Km (µM) kcat (min
-1
) relative activity 
CMP-5'-3APn 391 ± 61 2.04 ± 0.14 1.0 
CMP-5'-H3APn ND ND 6.7
a 
acetyl-CoA 19.5 ± 0.4 1.12 ± 0.03
b
 1.0 
propionyl-CoA 23.6 ± 4.2 0.089 ± 0.024
b
 0.080 ± 0.022 
malonyl-CoA ND ND 0.027 ± 0.006 
acetoacetyl-CoA ND ND 0.0044 ± 0.0013 
isobutyryl-CoA ND ND MS 
succinyl-CoA ND ND MS 
 
a
: substrate generated in situ with 10-fold excess FrbG 
b
: measured at 400µM CMP-5’-3APn 
ND: not determined 
MS: below UV detection limit; product observed by MS/MS only 
50 
 
2.7 Figures 
 
 
 
Figure 2.1: Substrates investigated in this study.  (a) Acyl-group acceptors.  (b) Coenzyme A 
acyl-donors. 
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Figure 2.2: Analysis of the non-enzymatic oxidation of the hydroxylamine product to its nitroso 
derivative.  (a) FrbG reaction mixtures were monitored by LC-MS following removal of the 
enzyme by diafiltration for loss of the hydroxylamine product (m/z = 459
-
).  (b) The nitroso 
derivative was reduced back to the hydroxylamine under anaerobic conditions using SmI2, but 
rapidly reformed upon exposure to air.  The left trace shows extracted ion chromatograms for the 
hydroxylamine (red curve) and the nitroso (blue curve), along with a significant CMP side 
product (green curve), following anaerobic reduction.  The right trace shows reformation of the 
nitroso (blue) following 30 minutes of aerobic exposure. 
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Figure 2.3: HPLC UV traces from reactions of FrbF with alternate acyl-CoA substrates.  The 
inset MS/MS trace on each plot shows fragmentation (at the position indicated by the arrow) of 
the expected parent ion for each product to the characteristic m/z = 322
-
 (CMP) daughter ion. 
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Figure 2.4: (a) The backbone of FrbF in complex with acetyl-CoA (Ac-CoA), showing the two-
domain architecture.  (b) Surface rendering of FrbF showing the acetyl-CoA binding cleft and 
the likely binding site for the phosphonate substrate.  Images generated by Satish Nair. 
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Figure 2.5: Active site residues within 6 Å of the acetyl-CoA thioester (center) selected for site-
directed mutagenesis. 
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Figure 2.6: Activity levels of each of the FrbF point mutants toward acetyl-CoA and CMP-5’-
3APn relative to the wild type enzyme. 
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Figure 2.7: The proposed mechanism for the N-acetylation of CMP-5’-H3APn catalyzed by 
FrbF. 
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Chapter 3: Directed Evolution of FrbF for Synthesis of FR-900098P 
and Characterization with its Target Enzyme from Plasmodium 
falciparum  
 
3.1 Introduction 
In the field of pharmaceutical development, the most desirable drug candidate is one that comes 
closest to being a so-called magic bullet; in other words, a drug that targets the root of the 
diseased state with no off-target effects.  It follows, then, that the best drugs for a parasitic 
disease such as malaria are those that are simultaneously toxic to the parasite itself but innocuous 
to the human host.  In order to achieve this sort of specificity for antimalarials, one can exploit 
the innate differences between the physiology of Plasmodium and humans.  One such difference 
is the pathway by which the isoprenoid precursors isopentynyl pyrophosphate (IPP) and 
dimethylallyl pyrophosphate (DMAPP) are synthesized. 
 
Isoprenoids are a very large and diverse family of biological compounds necessary to sustain 
life.  Included among them are sterols, which can help regulate membrane fluidity and serve as 
signaling molecules, and ubiquinones involved in electron transport for aerobic respiration.  In 
humans, the isoprenoid precursors IPP and DMAPP are synthesized via the mevalonate pathway, 
which was discovered in the 1950s (Figure 3.1a).  This pathway begins with acetyl-CoA, derived 
from central metabolism.  Condensation of two acetyl-CoA molecules yields acetoacetyl-CoA, 
which condenses with a third acetyl-CoA molecule to generate 3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA).  A subsequent reduction liberates mevalonic acid, which is then twice 
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phosphorylated.  Finally, decarboxylation yields IPP, which can be isomerized into DMAPP.  In 
Plasmodium falciparum, the enzymes necessary for the mevalonate pathway are absent; instead, 
orthologs of the non-mevalonate pathway enzymes are found [1].  Although discovered several 
decades after the mevalonate pathway, the non-mevalonate pathway, alternatively known as the 
2C-methyl-D-erythritol 4-phosphate (MEP) pathway or the 1-deoxy-D-xylulose 5-phosphate 
(DXP) pathway for its key intermediates, has been studied and characterized in great detail [2].  
This pathway begins with the condensation of pyruvate and glyceraldehyde 3-phosphate from 
central metabolism to produce DXP (Figure 3.1b).  Following a concomitant reduction and 
isomerization to MEP, the compound is conjugated to a cytidine monophosphate (CMP) moiety.  
Next, phosphorylation occurs at the 2-position, and the compound is subsequently converted to a 
cyclic diphosphate via loss of CMP.  Finally, a reductive ring opening occurs, and IPP and 
DMAPP are formed. 
 
The two pathways described above feature distinct biochemical transformations catalyzed by 
unique enzymes; as a result, each enzyme in the non-mevalonate pathway represents an ideal 
target for therapeutic intervention with minimal risk to the human host.  Recent efforts toward 
the discovery and development of non-mevalonate pathway inhibitors have focused on many of 
these enzymes as targets.  For example, the first enzyme in the pathway, DXP synthase (Dxs), 
can be inhibited by 5-keto clomazone, which is consequently used as an herbicide to block 
isoprenoid biosynthesis in the chloroplast [3].  Additionally, 3-(4-chloro-phenyl)-5-benzyl-4H-
pyrazolo[1,5-a]pyrimidin-7-one, a known inhibitor of mammalian transketolase superfamily 
members, has been explored as a scaffold for the design of novel Dxs inhibitors for tuberculosis 
treatment [4].  Inhibitors of other pathways enzymes, including 4-diphosphocytidyl-2C-methyl-
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D-erythritol synthase (Cms), 4-diphosphocytidyl-2C-methyl-D-erythritol kinase (Cmk), and 2C-
methyl-D-erythritol 2,4-cyclodiphosphate synthase (Mecds), have also been reported, and are 
reviewed in the recent publication by Obiol-Pardo and co-workers [5]. 
 
The discovery and design of inhibitors of the second non-mevalonate pathway enzyme, DXP 
reductoisomerase (Dxr), have predominantly focused on the fosmidomycin scaffold; these efforts 
were reviewed in the previous chapter.  To evaluate the effectiveness of fosmidomycin and FR-
900098 as Dxr inhibitors, inhibition parameters have been determined with Dxr enzymes from 
multiple species (Table 3.1).  Kuzuyama and co-workers first determined the inhibition constant 
of fosmidomycin against the Dxr from E. coli (EcDxr) to be 38 nM, and characterized the 
compound as a competitive inhibitor [6].  Later on, evidence was found for slow, tight-binding 
inhibition of EcDxr by fosmidomycin, with a subsequent Ki
*
 value of 21 nM [7].  Fosmidomycin 
inhibition constants have also been measured for Zymomonas mobilis Dxr (ZmDxr), where Ki 
was found to be significantly greater [8], and Synechocystis sp. PCC6803, which was found to 
have a comparable Ki value to EcDxr but a lower Ki
*
 [9].  This study also measured the Ki
*
 for 
FR-900098 with Synechocystis sp. PCC6803 Dxr, and found it to be ~5-fold lower than that of 
fosmidomycin.  Finally, IC50 values have been measured for both fosmidomycin and FR-900098 
against Dxr from E. coli, Pseudomonas aeruginosa (PaDxr), and P. falciparum (PfDxr) [10, 11].  
Of these three targets, both compounds were most effective against PfDxr.  Nevertheless, Ki 
values have not yet been determined with PfDxr. 
 
Also useful in the study of new Dxr inhibitors is X-ray crystallographic data of the enzyme-
inhibitor complex, such that the molecular basis for inhibition can be established.  Multiple Dxr-
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fosmidomycin co-crystal structures have been solved, including those of E. coli [12-14], 
Mycobacterium tuberculosis [15], and Thermotoga maritima [16].  However, these enzymes 
share only modest sequence identity with that of P. falciparum, and so their utility in the design 
of novel antimalarials is limited. 
 
Here, it is our goal to develop a screening method suitable for the identification of mutants of the 
N-acetyltransferase FrbF capable of utilizing new acyl-donor substrates for the synthesis of novel 
FR-900098 derivatives.  We will utilize the PfDxr enzyme as a tool to assess the efficacy of 
novel FR-900098 derivatives relative to the parent compound.  The enzyme will be characterized 
kinetically and inhibition constants will be measured with fosmidomycin, FR-900098, and novel 
derivatives thereof.  Further, insights gained from solution of the crystal structure in complex 
with its inhibitors will aid in the design of new PfDxr inhibitors for future drug development 
studies.   
 
3.2 Results and Discussion 
3.2.1 PfDxr: the target enzyme from Plasmodium falciparum 
3.2.1.1 Recombinant expression in E. coli 
As described in the previous chapter, it is our goal to harness the natural biosynthetic pathway of 
FR-900098 production to generate novel N-acylated derivatives.  The ultimate goal of this 
project, however, is not just to synthesize new compounds, but to discover among these 
derivatives more potent antimalarial drugs.  It is important to remember that fosmidomycin and 
FR-900098 are naturally produced as Streptomycete secondary metabolites, and not as human 
antimalarials.  Thus, these compounds are not optimized as PfDxr inhibitors, and so there is 
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likely room for improvement on this front.  Studies by Jomaa and co-workers first demonstrated 
via in vivo studies in three different P. falciparum strains that although they differ only in their 
N-acylations, FR-900098 is a more potent inhibitor of parasite growth than fosmidomycin, 
exhibiting IC50 values 2- to 3-fold lower than those of fosmidomycin [17].  Further, although 
they did not quantify any inhibition values, they demonstrated inhibition of the purified 
recombinant PfDxr enzyme by both compounds, with FR-900098 again showing greater 
effectiveness. 
 
To develop a means to evaluate the antimalarial potential of novel FR-900098 derivatives, we 
elected to heterologously express and purify the PfDxr target enzyme in E. coli.  Deviating 
slightly from the literature precedent, we first obtained a complete dxr gene codon-optimized for 
expression in E. coli, including the coding sequence for the 72 amino acid leader peptide.  
Following transformation of the BL21(DE3) expression strain with this construct, numerous 
efforts were made to express the heterologous protein.  However, SDS-PAGE analysis revealed 
neither soluble nor insoluble expression, and subsequent efforts to purify even trace amounts of 
the protein were unsuccessful (data not shown). 
 
As a result, the core of the gene without the first 216 nucleotides, which appear to code for an 
endoplasmic reticulum signal peptide and an apicoplast targeting sequence [17], was cloned into 
a separate vector and used to transform BL21(DE3).  SDS-PAGE analysis of expression cultures 
revealed apparent overexpression of the truncated protein, but predominantly in insoluble form.  
Following optimization of expression conditions, including expression temperature, IPTG 
concentration, and total culture volume, the pure PfDxr protein was successfully purified, as 
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confirmed by SDS-PAGE.  To demonstrate activity of the pure protein, an assay with the native 
substrates NADPH and DXP was carried out, demonstrating reduction in absorbance at 340 nm 
indicative of NADPH oxidation (Figure 3.2).  To prove that this activity was due to the PfDxr 
enzyme itself and not a contaminating protein, the assay was repeated in the presence of 
fosmidomycin, demonstrating nearly complete inhibition. 
 
3.2.1.2 Kinetic characterization 
Although the PfDxr enzyme has previously been studied [17], it has yet to be kinetically and 
structurally characterized.  Nevertheless, limited kinetic parameters have been determined for 
other DXP reductoisomerase enzymes from different species.  For example, Kuzuyama and co-
workers determined the DXP Km and kcat for the E. coli Dxr to be 250 µM and 59 min
-1
, 
respectively, in the presence of Mn
2+
 as the divalent cation [18].  Interestingly, the Km value 
decreased in the presence of Mg
2+
 or Co
2+
, although kcat decreased as well.   Grolle and co-
workers reported the Dxr from Z. mobilis to have a comparable Km of 300 µM with a Vmax of 
19.5 U mg protein
-1
, which is equivalent to a kcat of ~13 s
-1
 assuming a molecular weight of 40 
kDa [8].  For P. aeruginosa, a lower Vmax of 11.9 U mg protein
-1
 (kcat of ~8 s
-1
) was observed 
[10].  Argyrou and Blanchard studied divalent cation specificity of the Dxr from M. tuberculosis, 
finding little difference between Co
2+
 and Mn
2+
, which both outperformed Mg
2+
 [19].  
Nevertheless, they did not rule out the biological relevance of Mg
2+
, as intracellular levels of this 
cation are typically much greater than those of the other two.  Depending on the metal ion, they 
determined the Km for DXP to be between 4 and 100 µM, with kcat ranging from 1.6 to 5.0 s
-1
. 
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Based on the conditions presented in the Dxr kinetic studies and inhibition studies described 
above and in the subsequent section, we elected to measure the kinetics of PfDxr in the presence 
of Mn
2+
, as the greatest or near-greatest activities have typically been observed with this divalent 
cation [8, 19, 20].  Only NADPH was evaluated as the co-factor, as no Dxr protein has been 
identified with preference toward NADH.  To conserve materials and purified enzyme, assays 
were first attempted in a microtiter plate format in a total volume of 100 µL per well.  However, 
results obtained in this format were largely inconsistent (data not shown), and so a more robust 
platform was sought.  Activity measured in a cuvette in a total volume of 300 µL proved to be 
much more reproducible.  However, it was observed that subsequent kinetic trials carried out 
using the same aliquot of purified enzyme yielded kcat values that decreased with time.  In 
contrast, the calculated Km values did not change significantly with time, indicating that the 
enzyme is not highly stable in solution, even when kept on ice.  As a result, a fresh aliquot of 
PfDxr (stored at -80 °C in 15 % glycerol) was used for all subsequently performed assays to try 
to minimize loss of activity. 
 
The resulting kinetic parameters are shown in Table 3.2.  Interestingly, the Km value of 52 µM 
obtained for PfDxr is significantly lower than the value reported for EcDxr in the presence of the 
same divalent cation.  This suggests that the PfDxr enzyme is particularly well suited to bind 
DXP, which may have implications for the binding of inhibitors as well.  The observed kcat value 
of 120 min
-1
 is approximately twice that of EcDxr, but not as great as those obtained for the other 
species described above.  Overall, these kinetic parameters are most similar to those obtained for 
MtDxr with Mg
2+
 (Km = 42 µM, kcat = 2.1 s
-1
) [19]. 
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3.2.1.3 Structure elucidation with fosmidomycin and FR-900098 
Along with biochemical characterization of PfDxr activity, it is our goal to better understand the 
molecular basis for PfDxr inhibition by fosmidomycin and FR-900098.  As a result, the x-ray 
crystal structure of PfDxr in complex with each of these inhibitors, along with the co-factor 
NADPH and the divalent cation Mn
2+
, was solved in collaboration with Brian Bae and Zhi Li of 
Satish Nair’s group at the University of Illinois, Urbana-Champaign.  As mentioned in the 
Introduction, there are multiple structures of Dxr enzymes available, some of which have been 
co-crystallized with the fosmidomycin inhibitor.  Nevertheless, utilization of these structures for 
drug design has yet to generate any new leads, and so it is likely that there are key differences 
between PfDxr and the currently available structures. 
 
The co-crystal structures with fosmidomycin and FR-900098 were solved to resolutions of 1.9 Å 
and 2.2 Å, respectively.  In both structures, the hydroxamate moiety of the inhibitor coordinates 
to the Mn
2+
 ion via its two oxygen atoms, as shown in Figure 3.3.  Additionally, the N-acyl 
moiety inserts into a hydrophobic binding pocket formed by Trp-296, Met-298, Met-360, and the 
nicotinamide ring of the cofactor.  The presence of this pocket justifies the increased potency of 
FR-900098 relative to fosmidomycin as a PfDxr inhibitor, and suggests that further hydrophobic 
extension of the N-acyl side chain could provide even better binding to the active site.  At the 
other end of the molecule, the phosphonate moiety interacts favorably with residues Ser-269 and 
His-293 via hydrogen bonding interactions. 
 
Comparison of our PfDxr structure to the EcDxr co-crystal structure with the co-factor and 
fosmidomycin reveals key differences that suggest increased potency of the inhibitor toward 
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PfDxr.  For example, PfDxr possesses a narrower substrate-binding cavity, with movement of 
Met-298 toward the N-acyl moiety to form the aforementioned hydrophobic pocket.  
Concomitantly, H-293 moves into a position in which it can hydrogen bond with the 
phosphonate end of the inhibitor.  The equivalent residues in EcDxr (His-208 and Met-213) are 
not positioned well for either of these interactions.  An additional difference is seen at the 
position of Ser-269 in the PfDxr structure, which can also hydrogen bond with the phosphonate.  
In EcDxr, Gly-184 occupies this space and thus cannot hydrogen bond. 
 
To evaluate these interactions biochemically, the Ser-269Ala and Met-298Ala mutants were 
constructed.  Following purification, both mutants were assayed for activity.  While the S269A 
mutant was capable of turning over NADPH and was inhibited by fosmidomycin, the M298A 
mutant was inactive.  A repeated attempt at purification of the M298A mutant again yielded the 
inactive enzyme.  This likely indicates that this active site residue is catalytically requisite, and 
might be involved in maintaining structural integrity of the active site or positioning the substrate 
for catalysis.  Inhibition assays were carried out with the active S269A mutant, and an increase in 
the Ki value for fosmidomycin from 7.5 nM to 9.8 nM was observed.  This demonstrates that this 
residue’s interaction with the inhibitor is partly responsible for the superior inhibition of PfDxr 
by fosmidomycin relative to EcDxr. 
 
3.2.2 FR-900098P 
3.2.2.1 Synthesis in vitro 
As described in the previous chapter, we evaluated several alternate acyl-CoA substrates with 
FrbF to determine the ability of the wild type enzyme to synthesize novel FR-900098 
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derivatives.  Unsurprisingly, the greatest relative activity level (~8 % compared to acetyl-CoA) 
was observed with the structurally most similar propionyl-CoA substrate.  Based on our 
observations of a hydrophobic binding pocket to accommodate the N-acyl moiety in the PfDxr 
co-crystal structure, we selected the N-propionyl FR-900098 derivative, which is here called FR-
900098P, as a target for synthesis and subsequent characterization. 
 
Synthesis of FR-900098P was first attempted through sequential reactions with the purified 
FrbH, FrbG, and FrbF enzymes.  After each step, the enzyme was removed via diafiltration and 
products were isolated via HPLC fractionation.  However, this procedure resulted in almost 
undetectable amounts of the penultimate product, CMP-5’-FR-900098P.  This was likely due to 
the non-enzymatic oxidation of the hydroxylamine intermediate, CMP-5’-H3APn, to its nitroso 
derivative, as described in the previous chapter.  In an attempt to prevent this undesired side 
reaction, the FrbG and FrbF reactions were instead performed simultaneously, such that the 
hydroxylamine product of FrbG could immediately be acylated by FrbF.  This was found to 
increase the amount of CMP-FR-900098P generated, such that it became easily detectable by 
HPLC (Figure 3.4a).  Following purification of this product, CMP cleavage was performed by 
addition of FrbI.  Previously, FrbI had been revealed to be highly promiscuous in its nucleotide 
hydrolase activity, and so cleavage of CMP from the final product was always carried out in a 
separate reaction [21].  The identity of the newly synthesized product was confirmed by tandem 
MS/MS (Figure 3.4b).  In positive mode, FR-900098 undergoes a characteristic 198138 
fragmentation, indicating loss of both the N-acetyl and N-hydroxyl moieties.  As expected, we 
observed the same characteristic fragmentation (212138) for FR-900098P. 
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3.2.2.2 Synthesis in vivo 
While in vitro synthesis with purified enzymes is suitable for the production of small amounts of 
FR-900098P, it is not suitable for large-scale production given the cost of protein purification 
and of the substrate materials, particularly propionyl-CoA and NADPH.  Instead, a commercially 
viable process would likely follow either a completely synthetic approach or a biocatalytic 
approach using whole cells as “microbial chemical factories.”  Between these two alternatives, 
there are many advantages to utilizing a biosynthetic framework for the synthesis of value added 
products [22].  For example, chemical syntheses often require expensive, hazardous, or non-
renewable raw materials, and can also require harsh operating conditions.  Microbial 
biosyntheses, in contrast, can be performed using renewable biomass as a primary feedstock, and 
require only very mild operating conditions.  Additionally, biosynthetic machinery can access 
complicated reactions and specific stereochemistry that would otherwise be very difficult or even 
impossible to achieve by synthetic means. 
 
As a result, we sought to demonstrate the total synthesis of FR-900098P in vivo using an E. coli 
host.  Previous work in the Zhao lab has already demonstrated synthesis of FR-900098 in E. coli 
[21], which represents the first heterologous synthesis of a phosphonate in this host.  In this 
approach, the biosynthetic genes frbA through frbH were cloned into three compatible plasmids 
with three different antibiotic resistance markers, and each gene was placed under the control of 
an IPTG-inducible T7 promoter.  Following transformation into strain BL21(DE3), production of 
FR-900098 up to 6 mg/L was observed in selective LB media after 40 hours of growth at 30 °C.  
In the synthesis of FR-900098P, we first attempted to identify the product from the FR-900098 
producing strain described above, given that E. coli can naturally produce propionyl-CoA and 
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that the wild type FrbF enzyme can accept propionyl-CoA as a substrate.  However, no FR-
900098P was detected, likely indicating that intracellular propionyl-CoA concentrations are too 
low to generate detectable amounts of the product.  To overcome this problem, we investigated a 
mutasynthetic approach by which sodium propionate was fed to the culture at the time of 
induction.  Once taken up by the cell, propionate can be converted to propionyl-CoA via the 
propionyl-CoA synthetase gene prpE, which can then be utilized by FrbF.  As shown in Figure 
3.5a, this approach proved to be successful, and FR-900098P was detected in the cell culture 
broth by MS/MS.  FR-900098, however, was still the dominant phosphonate product, and FR-
900098P represented only ~5 – 8 % of the total phosphonate yield. 
 
In an attempt to further increase FR-900098P production in vivo using the native FR-900098 
biosynthetic machinery, a metabolically engineered E. coli host was investigated.  In general, to 
increase flux through a secondary metabolite pathway, a driving force needs to be created.  One 
method by which to accomplish this goal is to engineer the host’s metabolism to over-produce a 
key substrate for a rate-limiting step.  In the case of FR-900098P, it is likely that the FrbF-
catalyzed acylation is slow, given the relatively low activity observed with the non-native 
substrate.  To overcome this, then, propionyl-CoA concentrations in the cell can be increased via 
two modifications.  First, over-expression of prpE can increase the rate at which propionyl-CoA 
is synthesized.  Second, deletion of the prpRBCD operon prevents propionyl-CoA from being 
consumed in primary metabolism via conversion to succinate and pyruvate.  Both of these 
modifications have been reported in the literature and successfully utilized in the heterologous 
production of secondary metabolites [23].  As a result, we obtained this engineered strain, called 
BAP1, from the Blaine Pfeifer lab at Tufts University.  To engineer the BAP1 strain for FR-
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900098P production, it was simultaneously transformed with the three compatible plasmids 
containing the FR-900098 pathway via electroporation.  Following selection on LB media with 
three antibiotics, a colony was isolated containing all three plasmids.  Diagnostic PCR 
amplification of a pathway gene from each plasmid confirmed the presence of all three in the 
strain.  Production of FR-900098P in this host was analyzed under identical growth conditions as 
the BL21 host.  Relative to cell culture density, the FR-900098P titer increased 3.5-fold in the 
BAP1 strain as compared to the BL21 strain (Figure 3.5b).  However, it was observed that the 
BAP1 strain did not reach as high a density as the BL21 strain, resulting in an overall increase in 
endpoint FR-900098P concentration of only ~50 %.  This is likely due to the increased metabolic 
burden placed on the BAP1 strain by over-expressing prpE under a T7 promoter while 
simultaneously limiting its ability to utilize the exogenous propionate for central metabolism.  As 
observed in the BL21 strain, the BAP1 strain also produced FR-900098 as its primary 
phosphonate product.  However, the relative amount of FR-900098P was significantly greater in 
BAP1, comprising ~22 – 25 % of the total phosphonate yield. 
 
3.2.2.3 PfDxr inhibition studies 
Having demonstrated synthesis of FR-900098P both in vitro and in vivo, it was our goal to 
determine whether or not this compound is actually a promising antimalarial drug candidate.  
Thus, we carried out inhibition studies with the purified PfDxr target enzyme.  For comparison, 
inhibition constants for both fosmidomycin and FR-900098 were first determined (Table 3.2).  
To calculate these values, rate measurements were made for multiple substrate concentrations at 
multiple concentrations of each inhibitor.  Double-reciprocal plots for each inhibitor showed 
intersection at the vertical axis, indicating competitive inhibition made manifest by an increase in 
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Km only.  From the measured Km values, the inhibition constants for fosmidomycin and FR-
900098 were determined to be 7.5 nM and 3.7 nM, respectively.  These values correlate very 
well with the in vivo IC50 values measured against both the HB3 strain (350 nM for 
fosmidomycin, 170 nM for FR-900098) and A2 strain (370 nM for fosmidomycin, 170 nM for 
FR-900098) of P. falciparum [17].  Both values are significantly lower than the 38 nM inhibition 
constant reported for EcDxr, and are more comparable to the values reported for Synechocystis 
sp. PCC6803 (4 nM for fosmidomycin, 0.9 nM for FR-900098) [6, 9].  After we had carried out 
these measurements, Behrendt and co-workers published very similar PfDxr inhibition constants 
of 8.4 nM for fosmidomycin and 2.6 nM for FR-900098, which further justify the validity of our 
inhibition assay and the results derived therefrom [24]. 
 
Preparation of pure FR-900098P for inhibition studies was performed from the in vitro reaction 
mixtures, as the in vivo culture broth contains numerous contaminating compounds that are 
difficult to separate completely from the desired product.  The amount of product generated was 
quantified by weighing the lyophilized product, and was further checked via measurement of the 
LC-MS extracted ion peak area and by comparison to the concentration of the CMP-conjugated 
intermediate prior to treatment with the nucleotide hydrolase FrbI, which could be quantified via 
measurement of the UV absorbance peak area at 254 nm.  Kinetic measurements at multiple 
inhibitor concentration yielded a sub-nanomolar inhibition constant of 0.92 nM, indicating a 
significantly more potent inhibitor than fosmidomycin and FR-900098.  This result correlates 
very well with the observation of a hydrophobic binding pocket in the PfDxr crystal structures. 
 
71 
 
3.2.3 Directed evolution of FrbF 
3.2.3.1 Screening method development 
As described above and in the previous chapter, the N-acetyltransferase FrbF in the FR-900098 
biosynthetic pathway can accept, to a limited extent, alternate acyl-CoA substrates to synthesize 
alternate FR-900098 derivatives.  Nevertheless, activity is significantly reduced when alternate 
substrates are used, limiting the ability to synthesize novel derivatives both in vitro, where yield 
is poor, and in vivo, where competition with acetyl-CoA leads to a predominance of FR-900098 
in the total phosphonate product pool.  As a result, it would be desirable to identify mutants of 
FrbF that demonstrate increased activity toward non-native acyl-CoA substrates. 
 
To achieve this goal, we developed a screening method to detect FrbF activity in cell lysates in a 
high-throughput manner.  This method relies on 5,5’-dithiobis-(2-nitrobenzoic acid), known as 
DTNB or Ellman’s reagent, to detect the free coenzyme A product of the acyltransfer reaction 
[25].  Following a FrbF catalytic cycle, coenzyme A is generated, which possesses a free 
sulfhydryl terminus.  DTNB can participate in a rapid, non-enzymatic disulfide exchange with 
this product, liberating 2-nitro-5-thiobenzoic acid (TNB).  TNB has a large extinction coefficient 
at a wavelength of 412 nm, and as a result its formation can readily be measured.  The overall 
flowchart of the FrbF screening procedure is outlined in Figure 3.6. 
 
Initially, a short, kinetic assay was envisioned, with TNB formation measured continuously 
following addition of DTNB and the substrates to the assay plate.  However, numerous efforts to 
optimize assay conditions, including substrate concentrations, DTNB concentration, and assay 
time, repeatedly yielded inconsistent results with poor signal-to-noise ratios.  This is likely due to 
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side reactions between DTNB and other thiol-containing compounds present in cell lysate.  
Partial purification of FrbF via in-well capture on Ni-NTA resin was attempted to lower 
background, but yielded similarly inconsistent results.  As a result, the kinetic assay was 
abandoned in favor of an endpoint assay.  To determine an ideal assay time, reaction mixtures 
containing the substrates CMP-5’-3APn and acetyl-CoA as well as DTNB were incubated with 
cell lysates harboring either the empty pET28a vector or a pET28a-FrbF construct containing the 
wild type enzyme.  As shown in Figure 3.7a, the background begins to level out at ~30 min, 
while the FrbF signal continues to increase until ~120 min.  Thus, it was deemed that a two-point 
assay, with measurements taken at 30 min and 120 min and subtracted, would give the best 
signal-to-noise ratio.  Initial tests of this assay yielded significant variation about the mean (as 
high as 42 %), but with refinement of technique the variation was reduced significantly to ~14 % 
of the mean. 
 
To further improve the assay, it would be best to screen with the native hydroxylamine 
phosphonate substrate, CMP-5’-H3APn, rather than CMP-5’-3APn, the primary amine surrogate.  
As described in the previous chapter, however, this substrate is oxygen-sensitive, and as a result 
is impractical to prepare.  Thus, we instead evaluated in situ generation of this substrate via 
addition of FrbG to the assay mixture.  Curiously, FrbG activity was significantly reduced in the 
presence of DTNB, likely due to interactions with sulfhydryl groups in the protein itself.  As a 
result, the two-point assay protocol was amended such that the cell lysate was split between two 
plates, and DTNB was only added immediately prior to measurement.  In situ CMP-5’-H3APn 
generation was found to significantly increase the output signal, such that the total assay time 
could be shortened to 60 min.  In a half-plate assay with the wild type enzyme and either acetyl-
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CoA or propionyl-CoA, variation in output signal was found to be very low (~6 % relative to the 
mean), with a signal-to-noise level of ~4 – 7 depending on the substrate (Figure 3.7b). 
 
3.2.3.2 Library creation and preliminary results 
To limit the size of the library of FrbF mutants that would need to be screened, we have chosen a 
site-directed approach to target only those residues that might be actively involved in blocking 
the incorporation of a larger acyl-CoA substrate.  Having determined the crystal structure of 
FrbF in complex with acetyl-CoA, we selected for saturation mutagenesis those residues located 
within 6 Å of the substrate acetyl group, with the exception of Thr-190 and His-193, which were 
found to be catalytically requisite.  The resulting sites targeted for saturation mutagenesis are 
Phe-80, Glu-187, Ser-188, Asn-189, Glu-231, and Phe-234.  Degenerate primers were designed 
at each of these sites such that a saturation mutagenesis library could be constructed via 
megaprimer PCR, as described below in the Materials and Methods section.  Following library 
transformation, multiple colonies from the Phe-80, Glu-231, and Phe-234 libraries were chosen 
and sequenced to confirm mutation only at the desired site.  The results of the sequencing 
indicated a different codon in each construct successfully sequenced with no off-target 
mutations. 
 
Screening is currently underway at each of the six positions identified above.  Propionyl-CoA 
has been chosen as the first acyl-CoA substrate due to the promising in vitro inhibition results 
obtained with FR-900098P.  At present, the Phe-80 and Phe-234 saturation mutagenesis libraries 
have been screened; however, only false positives have been obtained (data not shown).  
Screening with propionyl-CoA will continue at the remaining four positions.  If no positive hits 
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are obtained, a different acyl-CoA substrate can be explored.  Alternatively, a broader library 
creation method can be employed to incorporate mutations at other positions. 
 
3.3 Conclusions and Outlook 
In this study, we successfully expressed the target enzyme for FR-900098 and its derivatives, 
PfDxr, in E. coli and characterized its kinetic behavior with the sugar substrate DXP in the 
presence of the co-factor NADPH and the divalent cation Mn
2+
.  We also determined inhibition 
constants for both fosmidomycin and FR-900098, revealing the latter to be twice as potent an 
inhibitor.  Additionally, we structurally characterized the enzyme in complex with either 
fosmidomycin or FR-900098 in collaboration with Satish Nair’s lab.  Analysis of these structures 
revealed key differences between the Dxr enzymes from P. falciparum and E. coli, explaining 
the greater potency of the phosphonate inhibitors toward PfDxr.  Further, we discovered a 
hydrophobic binding pocket at the hydroxamate end of the inhibitor, suggesting that a 
hydrophobic extension at this position could provide even stronger inhibition.  Based on this 
finding, we synthesized and evaluated the novel N-propionyl derivative FR-900098P, which was 
found to have a significantly lower inhibition constant than the parent compound.  Synthesis of 
this compound was demonstrated both in vitro and in vivo, and a metabolically engineered E. 
coli host was employed to further increase the product titer.  Finally, a colorimetric screening 
method was developed to identify FrbF mutants with greater activity toward novel acyl-CoA 
substrates. 
 
Future efforts in this direction will focus both on identifying the most promising antimalarial 
drug candidates and improving their production in the heterologous host.  The screening assay 
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developed here can be utilized to identify FrbF activity toward any novel acyl-CoA substrate, as 
it relies only on detection of the free coenzyme A product.  As a result, it can be employed to 
pursue other FR-900098 derivatives beyond FR-900098P.  We are currently investigating other 
such derivatives to identify targets beyond propionyl-CoA for FrbF directed evolution of 
substrate specificity.  The best FrbF mutants will then be integrated into the FR-900098 gene 
cluster to improve heterologous production.  Additionally, further metabolic engineering efforts 
are actively being pursued in the Zhao lab.  Currently, the heterologous FR-900098 pathway in 
E. coli utilizes a strong T7 promoter for every pathway gene, which introduces a heavy 
metabolic burden on the cell.  To alleviate this burden, the expression levels of each gene need to 
be balanced.  Further metabolic engineering is also being investigated to increase overall flux 
through the FR-900098 synthetic pathway.  The results of both of these approaches will be 
readily applicable to the production of novel FR-900098 derivatives. 
 
3.4 Materials and Methods 
3.4.1 Materials 
The Escherichia coli cloning strain DH5α, expression strain BL21(DE3) and the expression 
vector pET28a were obtained from EMD Biosciences (San Diego, CA).  Antibiotics and 
isopropyl-β-D-1-thiogalactopyranoside (IPTG) were purchased from Gold Biotechnology (St. 
Louis, MO).  All chemicals, including all buffers, the reagents cytidine triphosphate (CTP) and 
2-amino-4-phosphonobutyrate (2APn), and all acyl-CoAs were purchased from Sigma-Aldrich 
(St. Louis, MO) except for the co-factor NADPH, which was purchased from Applichem 
(Darmstadt, Germany), and 1-deoxy-D-xylulose 5-phosphate (DXP), which was purchased from 
Echelon Biosciences (Salt Lake City, UT).  All PCR reagents and restriction enzymes were 
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purchased from New England Biolabs (Ipswich, MA), and DNA Miniprep and Gel Purification 
Kits were purchased from Qiagen (Valencia, CA).  All primers were synthesized by Integrated 
DNA Technologies (Coralville, IA).  Talon Cobalt immobilized metal affinity chromatography 
(IMAC) resin was purchased from Clontech Laboratories (Mountain View, CA).  All other 
materials were purchased from Thermo-Fisher Scientific (Pittsburgh, PA). 
 
3.4.2 Cloning, expression, and purification 
The complete dxr gene from Plasmodium falciparum was codon-optimized for expression in E. 
coli by DNA 2.0 (Menlo Park, CA).  The core enzyme sequence (without nucleotides 1-216, 
corresponding to the 72 amino acid leader peptide) was PCR amplified with added NdeI and 
HindIII restriction sites and cloned into the respective sites of vector pET28a, introducing an N-
terminal His6 tag to the protein.  E. coli BL21(DE3) was transformed with the resulting construct 
by electroporation.  Cells were grown in LB media supplemented with kanamycin (50 μg/mL) at 
37 °C to an OD600 of ~0.8, after which induction was carried out by addition of 0.5 mM IPTG at 
25 °C.  After 18 hr, the cells were harvested by centrifugation at 7500 rpm for 15 min and 
resuspended in 20 mM Tris-HCl (pH 7.65), 0.5 M NaCl, and 15 % glycerol supplemented with 1 
mg/mL lysozyme.  After a freeze-thaw cycle at -80 °C, the cell suspension was sonicated to 
ensure sufficient lysis.  The lysate was clarified by centrifugation, after which the His6-tagged 
protein was purified by affinity chromatography on TALON Superflow Co
2+
 resin (Clontech, 
Mountain View, CA) coupled to fast-performance liquid chromatography.  The eluted protein 
was washed three times in 50 mM HEPES (pH 7.25), concentrated, and stored in 15% glycerol at 
-80°C. 
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3.4.3 Generation of PfDxr mutants 
Mutants of the PfDxr enzyme were generated by the megaprimer PCR method.  Briefly, primers 
were designed at the site of interest containing the desired mutation such that a larger primer (a 
“megaprimer”) containing the mutation could be generated by PCR, using the regular forward or 
reverse primer as the second primer (whichever yielded the shortest PCR product).  Next, PCR 
amplification of the full-length mutant gene was carried out using the megaprimer at one end of 
the gene and the regular primer at the opposite end.  Finally, the full length gene containing the 
mutation was digested with NdeI and HindIII and ligated into the correspondingly digested 
pET28a vector backbone.  The ligation product was then used to transform the E. coli cloning 
strain DH5α.  Transformants were picked and grown in 5 mL LB + 50 µg/mL kanamycin.  Their 
plasmids were isolated and sequenced by the UIUC Core Sequencing Facility (Urbana, IL), and 
Sequencher software (Gene Codes Corporation, Ann Arbor, MI) was used to confirm the 
presence of only the desired mutation.  The correct plasmids were then used to transform the 
expression strain E. coli BL21(DE3), and frozen stocks of the resultant strains were stored in 15 
% glycerol at -80 °C. 
 
3.4.4 Kinetic assays 
All kinetic assays were carried out with N-His6-tagged PfDxr in 100 mM Tris-HCl buffer (pH 
7.5).  Determination of kinetic parameters was carried out in a total volume of 300 µL with 1 
mM MnCl2, 0.3 mM NADPH, and 50 nM enzyme while the DXP concentration was varied from 
0 – 250 µM.  Oxidation of NADPH was continuously monitored via absorbance at 340 nm in a 
Nanodrop 2000c spectrophotometer (Thermo Scientific, Wilmington, DE) at 37 °C for a 
maximum of 5 min.  All assays were performed in triplicate.  Michaelis-Menten kinetic 
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parameters were fit to the data using OriginPro 8 software (OriginLab Corporation, 
Northampton, MA).  Due to the instability of the PfDxr enzyme, a fresh aliquot was used for 
each independent assay. 
 
3.4.5 Inhibition assays 
All inhibition assays were carried out with N-His6-tagged PfDxr in 100 mM Tris-HCl buffer (pH 
7.5).  To determine inhibition constants for fosmidomycin, FR-900098, and FR-900098P, kinetic 
assays were performed at multiple concentrations of each inhibitor ranging from 0 – 10 nM.  At 
each inhibitor concentration, Km values were determined, with reactions carried out at 37 °C in a 
total volume of 300 µL with 1 mM MnCl2, 0.3 mM NADPH, and 50 nM enzyme while the DXP 
concentration was varied from 0 – 250 µM.  From the measured Km values, Ki values were 
determined using the equation for competitive inhibition.  This procedure was repeated in 
triplicate for each inhibitor. 
 
3.4.6 In vitro FR-900098P synthesis 
Synthesis of FR-900098P in vitro was carried out with the purified N-His6-tagged FrbF, FrbG, 
FrbH, and FrbI enzymes and commercially available substrates.  First, cytidine monophosphate-
5’-3-aminopropylphosphonate (CMP-5’-3APn) was synthesized in 50 mM HEPES buffer, pH 
7.25, containing 1.5 mM cytidine triphosphate (CTP), 3 mM 2-amino-4-phosphonobutyrate 
(2APn), 10 mM MgCl2, and ~10 µM FrbH with incubation at 30 °C for 4 hours, after which 
nearly complete conversion was observed.  Following removal of FrbH with a 10 kDa cutoff 
filter, CMP-5’-FR-900098P was synthesized by addition of 1.5 mM NADPH, 1.5 mM propionyl-
CoA, ~10 µM FrbF, and ~15 µM FrbG with incubation at 30 °C for 4 hours.  At this point, side 
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products such as CMP-5’-2-amino-4-phosphonobutyrate (CMP-5’-2APn), CMP-5’-N-propionyl-
3-aminopropylphosphonate (CMP-5’-P3APn), CMP, CDP, and NADP+ were removed via  
fractionation on an Agilent 1100 Series HPLC using an Alltech Prevail C18 column with 
isocratic 15 mM ammonium formate elution.  The resulting CMP-5’-FR-900098P was 
lyophilized and resuspended in double-distilled H2O.  Finally, CMP cleavage was carried out in 
10 mM Tris-HCl buffer, pH 7.5, by addition of ~10 µM FrbI with incubation at 30 °C for 4 
hours.  The final product titer was estimated from the concentration of CMP-5’-FR-900098P 
(measured by UV absorbance at 254 nm) and confirmed by dry weight of the final lyophilized 
product.  Correct identity and purity of the final product was determined using an Agilent XCT 
ion-trap MSD mass spectrometer, where the anticipated m/z = 212
+
 parent ion and m/z = 138
+
 
daughter ion were observed. 
 
3.4.7 In vivo FR-900098P synthesis 
Synthesis of FR-900098P in vivo was carried out in two different E. coli expression strains.  The 
first was a BL21(DE3) strain transformed with three compatible plasmids containing the entire 
FR-900098 biosynthetic pathway except for the nucleotide hydrolase FrbI.  This strain was 
previously prepared and described by Johannes and DeSieno, et al. [21].  The second FR-
900098P expression strain was prepared from the metabolically engineered BAP1 strain 
provided by Dr. Blaine Pfeifer, which has been genetically modified to block conversion of 
propionyl-CoA to succinate and pyruvate for central metabolism [23].  This strain was 
transformed with the same three-plasmid FR-900098 production system.  Successful 
transformation was confirmed by diagnostic PCR amplification of a pathway gene from each 
plasmid.  Both strains were cultured in 50 mL LB medium supplemented with kanamycin (50 
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µg/mL), ampicillin (100 µg/mL), and chloramphenicol (25 µg/mL) at 37 °C to an OD600 of ~0.8.  
At this point, expression of the FR-900098 pathway enzymes was induced at 30 °C by addition 
of 0.5 mM IPTG, as well as 20 mM sodium propionate to increase propionyl-CoA synthesis.  
Samples of culture supernatant were collected at multiple time points up to 94 hr and clarified 
via centrifugation at 13,200 rpm for 10 min.  Analysis of clarified samples was carried out on an 
Agilent XCT ion-trap MSD mass spectrometer with a 100 x 4.6 mm Synergi 4µ Fusion-RP 80A 
column (Phenomenex, Torrance, CA) using 0.1 % formic acid in H2O (mobile phase A) and 
acetonitrile (mobile phase B) with the following elution program: 0 % B to 40 % B over 10 min; 
40 % B to 100 % B over 3 min; and 100 % B for an additional 5 min.  Products were identified 
in positive mode by their expected m/z values (198 for FR-900098, 212 for FR-900098P) with 
the corresponding m/z = 138 daughter ion. 
 
3.4.8 FrbF library creation 
The FrbF crystal structure was visualized using Molecular Operating Environment software 
(Chemical Computing Group, Montreal, Canada).  Residues within 6 Å of the acetyl-CoA acyl 
group were selected as saturation mutagenesis candidates, with the exception of those identified 
as catalytically requisite.  Saturation mutagenesis was carried out using primers containing a 
randomized codon at the site of interest, and the mutant FrbF constructs were generated using the 
megaprimer PCR method described above.  Libraries of FrbF mutants were digested with the 
restriction enzymes NdeI and HindIII and ligated into the respective sites of the correspondingly 
digested pET28a vector.  Following transformation of BL21(DE3) and selection on LB plates 
containing kanamycin (50 µg/mL), plasmids were isolated from multiple colonies in each library 
and sequenced to confirm diversity at the targeted amino acid position. 
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3.4.9 FrbF screening method 
Screening of FrbF mutant libraries was performed in a high-throughput microtiter plate assay.  
Using sterile toothpicks, individual colonies were picked from library transformation plates to 
the wells of a 96-well plate containing 100 µL of LB medium supplemented with kanamycin (50 
µg/mL) per well.  Following overnight growth to saturation at 37 °C, 5 µL from each well was 
used to inoculated 100 µL of fresh LB + kanamycin in a separate plate.  This plate was then 
incubated at 37 °C until an average OD600 of ~1.2 was reached, at which point 100 µL of LB + 
kanamycin supplemented with 0.6 mM IPTG was added to each well, yielding a final 
concentration of 0.3 mM IPTG.  Induced plates were incubated at 30 °C overnight to allow FrbF 
overexpression.  Afterward, the cells were pelleted by centrifugation at 4000 rpm for 10 min and 
resuspended in 100 µL of 50 mM HEPES buffer (pH 7.25) supplemented with 1 mg/mL 
lysozyme.  Following incubation at room temperature for 30 min, the lysis plate was subjected to 
a freeze-thaw cycle at -80 °C.  Immediately before the assay was performed, the plate was 
thawed and the cell lysate clarified via centrifugation at 4000 rpm for 10 min at 4 °C.  To 
perform the assay, 30 µL of lysate from each well was added to two separate 96-well plates.  To 
the first plate was added 50 µL of 10 mM DTNB and 70 µL of 50 mM HEPES buffer (pH 7.25), 
and the absorbance at 412 nm was measured immediately.  To the second plate was added 70 µL 
of the assay mixture, which contained (final concentrations): 400 µM CMP-5’-3APn, 400 µM 
NADPH, 300 µM of the alternate CoA substrate, and 4.8 µM FrbG in 50 mM HEPES buffer.  
The second plate was incubated at 30 °C for 60 min, after which 50 µL of 10 mM DTNB was 
added to each well and the absorbance at 412 nm was measured.  The difference between the two 
measured absorbance values was taken as an estimate of the total amount of product generated. 
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3.6 Tables 
 
Table 3.1: Inhibition values reported with purified Dxr enzymes (all units are nM) 
 
 fosmidomycin FR-900098 
Species IC50 Ki Ki* IC50 Ki Ki* 
E. coli 50 38 21 51 -- -- 
P. falciparum 32 -- -- 18 -- -- 
P. aeruginosa 150 -- -- 150 -- -- 
Synechocystis sp. PCC6803 -- 57 4 -- -- 0.9 
Z. mobilis -- 600 -- -- -- -- 
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Table 3.2: Kinetic parameters measured for PfDxr (mean ± standard deviation) 
 
Km, DXP kcat Ki, fosmidomycin Ki, FR-900098 Ki, FR-900098P 
52 ± 13 μM 120 ± 30 min
-1
 7.5 ± 2.0 nM 3.7 ± 0.9 nM 0.92 ± 0.19 nM 
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3.7 Figures 
 
Figure 3.1: Synthesis of isoprenoid precursors via (a) the mevalonate pathway and (b) the non-
mevalonate pathway. 
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Figure 3.2: (a) Purity of the recombinant PfDxr enzyme was confirmed via SDS-PAGE 
(expected MW = 47 kDa), while (b) activity was confirmed by tracking NADPH oxidation in the 
presence or absence of fosmidomycin. 
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Figure 3.3: Co-crystal structure of PfDxr with (a) fosmidomycin and (b) FR-900098 reveals the 
hydrophobic binding pocket.  (c) Comparison of PfDxr (yellow) with EcDxr (blue) reveals more 
favorable interactions with the inhibitor in PfDxr.  Images generated by Satish Nair. 
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Figure 3.4: Enzymatic synthesis of FR-900098P.  (a) Co-incubation of FrbG and FrbF following 
the FrbH reaction yields a mix of UV active compounds, including: a, CDP; b, CMP; c, CMP-5’-
NO3APn; d, CMP-5’-3APn; e, CMP-5’-P3APn; f, NADP+; and g, CMP-5’-FR-900098P.  (b) 
MS trace showing synthesized FR-900098P (m/z = 212
+
) with the expected m/z = 138
+
 daughter 
ion. 
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Figure 3.5: In vivo biosynthesis of FR-900098P.  (a) MS trace showing phosphonates produced 
(FR-900098 = 198
+
, FR-900098P = 212
+
) in the presence or absence of exogenous sodium 
propionate.  (b) Comparison of relative FR-900098P concentrations produced in BL21 and 
BAP1. 
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Figure 3.6: Flowchart of screening method for detection of FrbF activity toward novel 
substrates.  Briefly, a saturation mutagenesis library of FrbF constructs is generated by 
megaprimer PCR and used to transform E. coli BL21(DE3).  Individual colonies are grown, 
induced, and lysed in a microtiter plate.  Following addition of lysate to the FrbF assay mixture, 
TNB formation is monitored at λ = 412 nm to detect FrbF activity. 
92 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Screening method development.  (a) The time course of a lysate assay shows  
activity of FrbF over a significant time period.  (b) Screening of several wells expressing wild 
type FrbF with either acetyl- or propionyl-CoA shows low variation about the mean and 
significant signal above background. 
 
